Contents

Foreword 4
Profile of the institute 6
Organizational structure 9
GXP – quality assurance according to international standards 10
Staff and institute budget performance 12
Board of trustees 13
CRC Hannover 14
Selected news 16

DRUG DEVELOPMENT

Our services: from drug candidate to proof of concept 20
Projects 24
Research on human embryonic hematopoiesis in a teratoma model 24
Antibody-mediated neutralization of specific intestinal bacteria 24
Pulmonary fibrosis: ex-vivo model for research and drug testing 25
Quantification of the local inflammation in the lung by MRI 25
Mobile patients instead of mobile challenge chambers 26
Production of therapeutic phages for efficacy and infection studies 26
Optimization of production cell lines by means of microRNA 27
Development of a robust CHO platform for protein production 27

CHEMICAL SAFETY AND ASSESSMENT

Our services: from risk analysis towards safe products 28
Projects 32
Risks from pyrrolizidine alkaloids in foods 32
DevTox website available in Chinese 32
Test of a method to identify novel chemical risks in the food chain 33
Light scattering sensor for the analysis of nanoaerosols 33
Studies on the hazardousness of carbon nanotubes 34
Cabin air quality in aircraft: investigation completed 34
Prediction of respiratory toxicity: prevalidation of the ex-vivo model PCLS 35
PLATOX: validated in-vitro toxicity data of graphene nanoplatelets 35
TRANSLATIONAL BIOMEDICAL ENGINEERING

Our services: from idea to safe medical device 36
Projects 40
Breath-activated administration of dry-powder aerosol to ventilated patients 40
Innovative antimicrobial shield for implants 40
FINAMI project: development of plug connectors for neuro-implants 41
Novel test method to help select the most appropriate inhaler 41

PERSONALIZED TUMOR THERAPY

Our services: from molecular analysis to personalized therapy 42
Projects 46
Development of preclinical models from circulating tumor cells 46
New mechanisms of early metastatic spread in breast cancer discovered 47

Contacts 48
Fraunhofer-Gesellschaft 52
Fraunhofer-internal networking 53

Names, dates, events 54
Publications 54
Theses 59
Invited lectures 59
Contributions to congresses and conferences 61
Active participation in committees 63
Teaching activities 64
Publicly funded research projects 65
Cooperation partners 66
Exhibitions, congresses and workshops 68
Prizes 69

Editorial notes 70
Dear Reader,

For Fraunhofer ITEM the year 2016 was a special year, not only because of its 35th anniversary. The institute was founded in Hannover as “Fraunhofer Institute for Toxicology and Aerosol Research ITA” in 1981 by aerosol physicist Prof. Werner Stöber and pathologist Prof. Ulrich Mohr, the latter an internationally renowned expert in the field of histopathological diagnosis in the respiratory tract of experimental animals. Some disciples of the founding fathers are still working at Fraunhofer ITEM and it is their merit that the institute has such outstanding expertise in the generation and analysis of aerosols and of their histopathologically visible toxicity upon inhalation. Today, 35 years later, the founders’ concept of setting up a research institute with expertise in inhalation toxicology continues to be highly relevant. The change in the institute’s management in 1996 and the following years were characterized in particular by the setup of a clinical research unit dedicated to experimental and clinical respiratory research and by a stronger focus being placed on the research-intensive interface between in-vitro, ex-vivo and in-vivo animal models on the one hand and the human target organism on the other hand. As a result, the scope of services and expertise offered by Fraunhofer ITEM was enhanced from translational toxicology for drugs and chemicals to include also translational medical research and clinical drug development, supported by an in-house proof-of-concept center. These clinical research and development capacities were combined with a pharmaceutical biotechnology department, set up and enhanced to include a GMP plant for process development and manufacturing of investigational biopharmaceuticals, and with the institute’s expertise in inhalation toxicology including a corresponding technology platform, making Fraunhofer ITEM a unique institution in the publicly funded research landscape in Germany and Europe. This enhanced expertise inevitably led to a change in the institute’s name from ITA to ITEM: Fraunhofer Institute for Toxicology and Experimental Medicine. As another step in Fraunhofer ITEM’s medical translational research, the new Division of Translational Biomedical Engineering and a corresponding Fraunhofer High-Performance Center with concurrent professorship at the Hannover Medical School were set up in 2016.

The end of the year 2016 was marked by a change in the institute’s management. Twenty years after the previous appointment of an institute director, my colleague Prof. Dr. med. Norbert Krug is now taking over as executive director. Prof. Krug played a pivotal role in setting up the institute’s clinical research department and the CRC Hannover. After my retirement at the end of March 2017, my position will finally be posted.

Let me take this opportunity to cordially thank all colleagues, friends and clients for many years of fruitful cooperation on the scientific and professional levels and often also in friendship. I hope you enjoyed this as much as I did. Please remain well-disposed towards Fraunhofer ITEM, its staff, and my successors – you will benefit from it.

Yours sincerely,

Uwe Heinrich
Research at Fraunhofer ITEM is focused on human health – and this has been so for over 35 years. The emphasis is on two aspects: firstly, on protecting health from potentially harmful, in particular airborne substances, be they gases, aerosols, particles, fibers, or nanomaterials, and secondly, on investigating and developing diagnostic and therapeutic approaches in the field of inflammatory and allergic respiratory conditions, both at the preclinical and clinical levels. The lung and the airways are at the focus of research and development, but Fraunhofer ITEM is also investigating other subject areas. Examples are the development and manufacturing of biopharmaceuticals, tumor therapy, and translational biomedical engineering.
Protecting human health

Health protection includes environmental, occupational, and consumer protection. Fraunhofer ITEM supports industry and public authorities in the early identification and prevention of health hazards from new products and processes and thereby also promotes sustainable development of Germany as a business location.

In this context, Fraunhofer ITEM scientists investigate novel products and processes whose potential health hazards are as yet unknown, such as different nanomaterials. They evaluate the human exposure situation and develop suggestions on how to reduce or eliminate these potential hazards. For the experimental part of risk assessment, Fraunhofer ITEM has at its disposal the necessary know-how and toxicological test methods, in particular in the field of inhalation toxicology. For the required tests, complex atmospheres and test aerosols can be generated at laboratory scale and exposure scenarios can be reproduced for in-vitro or in-vivo studies. Special computerized mathematical exposure models are also developed and used for this purpose.

The scientists perform exposure and risk assessment on behalf of clients, based on their own experimental studies, literature searches, and data provided by the client. They prepare reports on test substances and support clients in the registration of chemicals and complex mixtures and in the assessment of substances falling under the European chemicals regulation REACH.

Preclinical research and development

With regard to inflammatory and allergic diseases of the respiratory tract Fraunhofer ITEM offers research and development services: from the molecular level to clinical trials. Methods of cell biology and molecular biology are used to validate novel target structures for diagnosis and therapy and optimize these during early development stages. Once possible drug candidates have been identified, efficacy and safety tests are performed. Toxicological and safety pharmacological testing for drug registration is performed in compliance with GLP.

The institute offers a broad range of efficacy and drug safety studies and makes use of a variety of in-vitro test systems and models of inflammation, asthma, and lung infection. Using a tiered approach, the scientists first perform studies in cell culture models and subsequently gain further insights in complex tissue cultures and eventually in animal models. The use of human tissue in particular allows them to obtain human data at an early stage already, data of pivotal importance above all in the testing of biopharmaceuticals.

Throughout the entire research and development process, Fraunhofer ITEM scientists are keeping an eye on the ethical principle of the “3 Rs” – they are well aware of their great responsibility for the well-being of the animals they use in their experiments. The three Rs stand for Replacement – the use of alternative methods that avoid or replace the use of animals –, Reduction – strategies that will result in fewer animals being used – and Refinement – modification of husbandry or experimental procedures to minimize pain and distress. Research at Fraunhofer ITEM is geared to using less animals to answer research questions, to consistently improving research methods, and to replacing animal experiments by alternative methods whenever possible.

Biopharmaceutical manufacturing: from cell line to investigational medicinal product

A team of scientists, engineers and technicians in the institute’s facilities in Braunschweig advises and assists clients and cooperation partners in the development of novel biopharmaceutical agents – from the development of recombinant production cell lines via the manufacturing of master and working cell banks, bioprocess development and scale-up, to the manufacturing of pilot batches of the novel biopharmaceutical
agent and sterile fill and finish of investigational medicinal products in the form of infusion solutions or in vials or ampoules (in compliance with GMP guidelines).

**Early-phase clinical trials in the CRC Hannover**

Efficacy and tolerability testing of novel drugs in humans is the critical step in medical translational research. The Clinical Research Center Hannover (CRC Hannover) offers optimal conditions for performing this step: state-of-the-art infrastructure including a total of 50 beds, 30 of which allow intensive monitoring of study participants. Fraunhofer ITEM has specialized in conducting clinical trials for the registration of pharmaceuticals for the therapeutic areas of allergy, asthma, COPD, and pulmonary fibrosis. The focus is on proof-of-concept studies in compliance with GCP guidelines, managed by highly qualified physicians. An in-house GMP laboratory enables production of intravenous dosage forms of IMPs.

With the Fraunhofer Challenge Chambers, special facilities for controlled challenge are available. They are among very few of this kind worldwide. In these chambers, pollen, house dust mite and other allergens, and also ozone can be dispersed in the air in a precisely controlled manner. The efficacy of novel medications to treat seasonal allergic rhinitis, for example, can be tested there under controlled allergen challenge conditions. And in challenge studies with LPS or ozone, the clinical efficacy of new anti-inflammatory drugs can be verified. The temporary inflammation of the airways in healthy study participants induced by short-term controlled ozone inhalation challenge resembles the inflammatory condition seen in COPD patients.

An essential prerequisite for the setup, further development, and operation of the Fraunhofer Challenge Chambers is the comprehensive expertise and many years of experience of the institute’s aerosol technologists.

**Translational Biomedical Engineering**

Many years of experience of the institute’s aerosol technologists, in particular their know-how on the aerosolization of substances and on the deposition and kinetics of inhaled materials have led to the Department of Medical Inhalation Technology being set up in 2015. At the end of 2016, this eventually resulted in the new Division of Translational Biomedical Engineering and corresponding business unit. Focuses of this division are on conducting and assisting the development of novel technologies for administration of medicinal aerosols on the one hand, and on conducting and assisting the development of active implants on the other hand.

In spring 2017, the new High-Performance Center Translational Biomedical Engineering was inaugurated, aimed at bringing medical devices from the lab into phase I of clinical development. It offers support in particular to small and medium-sized enterprises and to research institutions, given that dedicated manufacturing processes for medical devices and also regulatory requirements such as the new EU-wide Medical Device Regulation represent substantial economic hurdles for them. Collaborators in this new High-Performance Center include the Hannover Medical School, Laser Zentrum Hannover, Leibniz Universität Hannover, and in particular the two clusters of excellence REBIRTH and “Hearing4all” (in Hannover), besides research consortia such as “Biofabrication for NIFE”, and Fraunhofer ITEM. The Center is funded by the Lower Saxony government and the Fraunhofer-Gesellschaft.
After 21 years of successful leadership, Prof. Uwe Heinrich ceded his position as Fraunhofer ITEM Executive Director to Prof. Norbert Krug on January 1, 2017.

Headed by the Institute Director(s) and the Executive Committee, Fraunhofer ITEM is organized in eight divisions. Two of these – “Translational Biomedical Engineering” and “Personalized Tumor Therapy” – were instituted at the beginning of 2017.

The Fraunhofer ITEM headquarters are in Hannover, the institute’s Division of Pharmaceutical Biotechnology has its facilities in Braunschweig on the campus of the Helmholtz Center for Infection Research, and the Division of Personalized Tumor Therapy is based in Regensburg’s BioPark.
Fraunhofer ITEM is striving to meet high quality standards with the services and products offered and to ensure maximum safety for trial subjects in clinical studies performed at the institute. Not only are the relevant legal regulations strictly complied with, but state-of-the-art regulatory requirements are invariably taken into consideration. To guarantee that the work performed at Fraunhofer ITEM satisfies internationally accepted quality standards, Fraunhofer ITEM has implemented the GXP quality assurance systems. These include Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and Good Manufacturing Practice (GMP). With their respective scopes of application, these quality assurance systems cover the translational approach in the institute’s spectrum of activities. The central service unit “Quality Assurance” is responsible for putting into practice the relevant quality assurance programs.

GLP compliance of non-clinical safety studies

To ensure reliability and traceability of the data generated in non-clinical health and environmental safety studies, the GLP principles include, among others, the following requirements:

– Clear assignment of responsibilities within the test facility
– Meticulous planning and qualified performance of every study
– Complete documentation of all procedures and preparation of comprehensive reports

By means of study-based and facility-based inspections, the service unit “Quality Assurance” continuously monitors compliance with these principles in the institute’s departments that are concerned with toxicology, safety pharmacology, and analytics. For more than two decades, the competent authorities have performed regular inspections and have certified the institute’s GLP compliance for a broad range of studies. The established quality assurance system thus guarantees to all sponsors an internationally recognized quality standard in the institute’s non-clinical departments.

GCP standard of clinical trials

The ethical principles for biomedical research laid down in the Declaration of Helsinki form the basis of the GCP principles describing the quality standards to be met in clinical trials. At Fraunhofer ITEM, a broad range of measures ensures that these requirements are met in trials falling under the German Drug Act and performed on behalf of international sponsors and also in clinical research projects. The service unit “Quality Assurance” assists the clinical investigators in fulfilling their responsibilities by closely monitoring implementation of the quality-relevant processes under aspects of GCP and by routinely checking the corresponding documentation. The institute’s sponsors have rated the quality level reached as GCP-compliant.

In the Clinical Research Center Hannover (CRC Hannover), cooperated as a Fraunhofer research institution by Fraunhofer ITEM, the Hannover Medical School (MHH) and the Helmholtz Center for Infection Research (HZI), the service unit “Quality Assurance” performs cross-project and coordinating tasks in the field of quality assurance, thereby maintaining a high level of uniform quality standards in the CRC Hannover facilities. The synergies resulting from the scientific cooperation of the partners in the
CRC Hannover thus go hand in hand with guaranteed maximum protection of all trial subjects and fulfillment of sponsors’ quality requirements.

**GMP quality standard**

The Division of Pharmaceutical Biotechnology in Braunschweig has comprehensive expertise and a long track record in the development of GMP manufacturing processes for biopharmaceuticals. For this purpose, the division has established a GMP quality assurance system to ensure compliance with the German Drug Act, the German Ordinance on the Manufacturing of Medicinal Products and Active Ingredients (AMWHV), and the European Union GMP Guide. Other guidelines are also taken into account, e.g. those of the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use).

The division is operating clean rooms of grades D to B according to Annex 1 of the EU GMP Guide, subdivided into different zones satisfying the respective hygiene and pressure requirements, and using steam and water in the qualities prescribed by the European Pharmacopoeia. All critical equipment for the manufacture of medicinal products has been qualified in compliance with Annex 15 of the EU GMP Guide. An automated filling machine enclosed in a restricted-access barrier system (RABS) of clean-room grade A is available for manufacturing of small batches of sterile investigational medicinal products (IMPs) for use, for example, in clinical trials or stability tests.

The division has been inspected on numerous occasions by the competent authorities and has been granted a manufacturing license for active biopharmaceutical ingredients and investigational medicinal products.

Biopharmaceutical products can thus be developed jointly with small biotech start-ups and academic partners, and can consistently be manufactured to the required quality – from the cell line to the released IMP.

**CONTACT**

Dr. Ilona Fleischhauer  
Head of Quality Assurance at the Hannover site  
Phone +49 511 5350-304  
ilona.fleischhauer@item.fraunhofer.de

Dr. Neophytos Papamichael  
Head of Quality Assurance at the Braunschweig site  
Phone +49 531 6181-6200  
neophytos.papamichael@item.fraunhofer.de
At the end of 2016, Fraunhofer ITEM staff amounted to 303 persons:
- 8 apprentices
- 40 students (including Ph.D. students)
- 255 scientific, technical, and administrative staff

In 2016, the institute’s budget reached a level of 26.4 million euros. Financing by acquired funding amounted to 72 percent. The share of industrial income in the institute’s budget was 45 percent. Investments of Fraunhofer ITEM amounted to approximately 1.3 million euros.
The boards of trustees of the individual Fraunhofer Institutes act as purely advisory bodies to their institute’s management. The members come from academia, industry, and government agencies. In 2016, the Fraunhofer ITEM board of trustees was made up of the following members:

**Dr. Eckhard von Keutz**  
Chairman of the board or trustees  
Senior Vice President, Global Head Early Development,  
Bayer HealthCare AG

**Prof. Dr. Christopher Baum**  
Deputy Chairman of the board or trustees  
President and member of the Presidential Council responsible for the Division of Research and Teaching of the Hannover Medical School

**Dr. Marcus Beiner**  
Deputy Head of the Department Research and Innovation,  
Head of the Division of Life Sciences, Humanities, Social Sciences, and Sustainable Development,  
Lower Saxony Ministry of Science and Culture

**Prof. Dr. Dieter Bitter-Suermann**  
Former President and member of the Presidential Council responsible for the Division of Research and Teaching of the Hannover Medical School

**Prof. Dr. Ulrich Deschl**  
Head of Nonclinical Drug Safety,  
Boehringer Ingelheim Pharma GmbH & Co. KG

**Prof. Dr. Paul-Georg Germann**  
Head Preclinical Safety Germany, AbbVie Deutschland GmbH

**Prof. Dr. Thomas Jung**  
Executive Director, Jung & Partners GmbH, Switzerland

**Dr. Günther Karmann**  
Executive Director, Karmann Consulting GmbH

**Prof. Dr. Hillel S. Koren**  
Managing Director, Environmental Health, LLC;  
former Director Human Studies Division, United States Environmental Protection Agency;  
Research Professor Carolina Environmental Program, University of Carolina at Chapel Hill, USA

**Dr. Edgar Leibold**  
Vice President Product Stewardship, BASF SE

**Prof. Prof. h. c. Dr. med. Thomas Lenarz**  
Professor and Chairman of the Department of Otorhinolaryngology, and Director of Deutsches HörZentrum, Hannover Medical School

**Prof. Dr. Reinhard Pabst**  
Lower Saxony Professorship in Immunomorphology, Hannover Medical School

**Prof. Dr. Klaus F. Rabe**  
Medical Director and Executive Medical Officer, LungenClinic Grosshansdorf;  
Endowed Professorship in Internal Medicine/Pneumology, Faculty of Medicine, Kiel University

**Prof. Dr. Gerhard Schlüter**  
Consultant in toxicology;  
former Global Head Toxicology, Bayer HealthCare AG

**Dr. Thor A. Voigt**  
Medical Director Germany, Boehringer Ingelheim Pharma GmbH & Co. KG

**Dr. Torsten Wagner**  
Senior Vice President, Corporate Technical Operations, Merz Pharma GmbH & Co. KGaA
The Clinical Research Center Hannover (CRC Hannover) is a center for early-phase clinical trials that is the only one of its kind in Germany, used collaboratively by three well-established research institutions: Hannover Medical School (MHH), Helmholtz Center for Infection Research (HZI), and Fraunhofer ITEM. As a proof-of-concept center it provides a platform for safety and efficacy testing of novel drugs, diagnostic methods and medical devices on their way to marketing authorization. In addition to proof-of-concept trials, HZI is conducting the "German National Cohort" study, the largest health study in Germany, at the CRC Hannover. Over the next few years, 10,000 individuals will be examined and questioned here. The aim of the study is to provide information facilitating early detection, prevention, and treatment of wide-spread conditions such as cardiovascular and respiratory diseases, cancer, diabetes, dementia, infections, and diseases of the immune system. Since its inauguration in fall 2014, the CRC Hannover has become established as a leading-edge study center.

For the performance of phase-I studies (first-in-man trials with novel drugs to test their safety in a small number of volunteers) and phase-II studies (required to provide the proof of concept of novel medications or therapeutic approaches
In man), a total of 50 beds are available, 30 of which allow intensive monitoring of study participants. The technical equipment in the CRC Hannover enables comprehensive diagnostics, complemented by the additional infrastructure of the three cooperating research institutions.

The first-rate equipment available at the CRC Hannover allows the Fraunhofer scientists to do airway research at a high level. For example, they have at their disposal a cutting-edge MRI scanner with a xenon polarizer. This imaging technology allows them to visualize not only lung tissue, but also the air in the lungs and even the air passing into tissue. The establishment of this method represents a milestone, in particular for the search for biomarkers that are suitable to indicate whether lung tissue is healthy or diseased. Such diagnostic biomarkers in turn can then be used to develop new methods for drug testing.

The CRC Hannover furthermore hosts one of the most modern biobanks in Germany: the Hannover Unified Biobank (HUB) of the Hannover Medical School – a highly automated, state-of-the-art depository for biomaterials with affiliated preanalytics. This is a great benefit to the institutions cooperating in the CRC Hannover: it gives them the possibility to store biomaterials from patients required for medical research – under high quality standards. The HUB is one of only few biobanks in Germany that have been certified in accordance with DIN EN ISO 9001:2008.

The scientific activities of course are priority at the CRC Hannover. And yet, the representative building with its state-of-the-art technical equipment, spacious facilities and on-site catering service is used increasingly also as a conference center. The conference room with view into the greenery and a close-by terrace offers room for 120 participants. By coupling the conference room and the spacious foyer, a setting for 320 guests can be arranged. The CRC Hannover each year hosts, for example, the Fraunhofer seminar “Models of Lung Disease”, organized by Fraunhofer ITEM in close cooperation with the German Center for Lung Research (DZL). This two-day event provides an international platform for intense discussions between industry, academia and authorities about predictive disease models and translational lung research, accompanied by poster presentations and an industry exhibition. Another example of the CRC Hannover being used as a conference center is the “Pulmonary Fibrosis” patient seminar, organized at regular intervals by BREATH, the Hannover DZL site. The TRAIN Academy professional education program “Translational Research & Medicine: From Idea to Product” is yet another series of lectures the CRC Hannover hosts at regular intervals, besides numerous other external and internal events.

**CONTACT**

Prof. Dr. med. Norbert Krug
Phone +49 511 5350-8100
norbert.krug@item.fraunhofer.de
The seminar series “Models of Lung Disease” has meanwhile become a tradition at Fraunhofer ITEM. In January 2016, international experts in translational lung research got together for the 15th time to exchange ideas and share information. The aim of this seminar was to discuss new developments in experimental lung research from industry and academia and compare different models and approaches. Different disease areas, including asthma, COPD, pulmonary fibrosis, and lung infection, were addressed in selected presentations covering different phases of research, from basic research via preclinical models to early-phase clinical trials. Participants were highly satisfied with the well-balanced mixture of interesting presentations, personal conversations, and guided tours.

New mechanisms of early metastatic spread in breast cancer discovered

The dogma that cancer cells seed mainly from advanced tumors seems no longer tenable. Scientists of the Regensburg-based Fraunhofer ITEM Division of Personalized Tumor Therapy, the University of Regensburg and the Icahn School of Medicine at Mount Sinai in New York have discovered new mechanisms of early metastatic spread in breast cancer. Results were published in the renowned journal “Nature” at the End of 2016. The scientists are hoping that these fundamentally new findings will advance cancer research substantially.
November of Science – open house day

With a versatile program for adults as well as for children, Fraunhofer ITEM and CRC Hannover opened their doors to the public for one day in November 2016 to give insight into the broad spectrum of research activities for human health. Numerous visitors enjoyed guided tours to laboratories and the clinical facilities, lectures on research topics of current interest, and short hands-on trainings for youngsters from 8 to 14 years of age. The “November of Science” is a project of the Initiative Science Hannover, in which eight Hannover-based universities and Fraunhofer ITEM have been participating since its beginning in 2007.

Prizes for scientific work

Research work done at Fraunhofer ITEM was honored at various conferences and congresses in 2016, for example, by poster prizes or the opportunity to present a subject matter in a plenary talk. Two junior scientists were awarded poster prizes during the Annual Meeting of the German Center for Lung Research: Sebastian Konzok for his poster titled “Bacterial and viral PAMPs and cellular DAMPs lead to activation of the inflammasome in human lung tissue ex-vivo” and Arne Gaida for his poster titled “A dual-center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD.” At the same conference, the abstracts submitted by Helena Obernolte (disease area “Asthma & Allergy”) and Olaf Holz (disease area “COPD”) were selected for plenary presentations from among 230 submitted abstracts. Elaine Cabral Serrão was awarded a prize for her poster titled “A novel disruptive IgE inhibitor: efficacy assessment in non-human primate and human precision-cut lung slices” at the EAACI 2016 Congress. And at the ERS 2016 Congress, Christina Hesse’s abstract “Induction of pro-fibrotic biomarkers in precision-cut lung slices (PCLS)” won the award of “Best Abstract of Young Investigators”.
Workshop on in-vitro toxicology – focus on inhalation

The one-day workshop “Cell-based in-vitro methods for investigations on biological effects of inhalable compounds” in November 2016 gave scientists and consultants from academia and industry insights into the emerging field of in-vitro toxicology of inhalable substances. They learned about in-vitro methods as powerful and predictive methods enabling in-vitro investigation of the biological effects of airborne compounds in the sense of the 3Rs. Investigation of nearly all kinds of inhalable atmospheres, such as dry or droplet aerosols, sprays, emissions during use of consumer products, exhausts, and nanoparticles, is possible today using appropriate and relevant cell-based in-vitro methods.

EU-ToxRisk

Fraunhofer ITEM is participating in the European research project “EU-ToxRisk” that was kicked off in January 2016. Its aim is to lay new foundations for a paradigm shift in toxicology – towards more efficient and animal-free hazard and risk assessment of chemicals. An international consortium of 39 partner organizations from academia, industry and regulatory authorities is participating in this project receiving funding of 30 million euros. Fraunhofer ITEM is bringing in its expertise with a focus on inhalation toxicology: from alternative methods for assessment of inhalation toxicity to the development of in-silico methods for use in regulatory contexts.
High-Performance Center inaugurated

In spring 2017, the new High-Performance Center Translational Biomedical Engineering was inaugurated, aimed at bringing medical devices from the lab into phase I of clinical development and at helping in particular academic institutions and SMEs to overcome economic hurdles of the development process. The new Center is headed by Prof. Theodor Doll. Collaborators include the Hannover Medical School, Laser Zentrum Hannover, Leibniz Universität Hannover, and in particular the two clusters of excellence REBIRTH and “Hearing4all” (in Hannover), besides research consortia such as “Biofabrication for NIFE”, and Fraunhofer ITEM. The Center is funded by the Lower Saxony government and the Fraunhofer-Gesellschaft.

The focus of the new Center is on technological solutions for inhaled drug delivery, commonly referred to as smart drug devices, and on active implants, i.e. electrical stimulation systems such as cochlear implants. The photograph shows Prof. Lenarz (sitting at the front), Chairman of the Department of Otorhinolaryngology of the Hannover Medical School, demonstrating on a model the insertion of such an implant into a patient’s cochlea. His audience: Dr. Gabriele Heinen-Kljajić, Lower Saxony Minister of Science and Culture, Prof. Theodor Doll, Head of the High-Performance Center, Prof. Norbert Krug, Fraunhofer ITEM Director, Prof. Reimund Neugebauer, President of the Fraunhofer-Gesellschaft, and Prof. Christopher Baum, President of the Hannover Medical School (from left to right).
Our commitment to translating innovative drug research into therapeutic applications – safely, reliably and efficiently. Based on our scientific expertise, we offer appropriate methods and approaches to this end. With custom-tailored development strategies, we support our clients in process development for and manufacturing of active biopharmaceutical ingredients and sterile investigational medicinal products, in preclinical testing – both pharmacology and toxicology – and in early-phase clinical trials from first-in-human to the clinical proof of concept.

Our state-of-the-art equipment and innovative research approaches allow us to develop new methods and techniques – also in cooperation with our clients. Already in the early phase of drug development, we provide assistance as independent consultants and negotiators in the dialog between applicant and regulatory authority. We work in compliance with regulatory and legal requirements for drug development and according to the quality assurance systems GLP, GMP, and GCP.

With the services offered by Fraunhofer ITEM, we can cover either the complete drug development chain or individual phases on the way from the drug candidate to clinical trials.
Regulatory research and risk assessment in drug development

Fraunhofer ITEM has combined its expertise in drug research and development with its experience in registration and risk assessment of chemicals. With these forces joined, the institute is uniquely positioned to support clients in regulatory affairs in the drug development process. Our scientists explore, develop, and validate new approaches to manufacture, characterize, and test innovative medicinal products, ensure regulatory input on these approaches, and implement them in product development in cooperation with the client. Our service portfolio includes:

- Preparation of a regulatory strategy to take products from lab to market
- Interaction with regulatory authorities
- Preparation of the required documentation
- Risk assessment
- Regulatory research

Development of novel biopharmaceuticals

A multidisciplinary team of biologists, chemists, pharmacists, engineers, and technicians assists our clients on their way from the idea for a new biotherapeutic via development of a production cell line to GMP manufacturing of the investigational medicinal product (IMP) released for use in clinical trials. This team guides you along the entire regulatory pathway to your approved IMP dossier. Our clients benefit from our profound knowledge accumulated over 20 years from a broad range of biopharmaceutical candidates – from simple proteins to complex structures such as viruses and cells. Our service portfolio includes:

- Biopharmaceutical, technical, and regulatory consultancy
- Development of mammalian and microbial production cell lines
- GMP manufacturing of master and working cell banks
- Development of complex upstream and downstream sequences with subsequent upscaling
- GMP manufacturing of API pilot charges
- Release testing of biopharmaceutical APIs and IMPs
- Sterile manufacturing and release of IMPs (liquid dosage forms)
Preclinical testing

For preclinical development of a drug candidate we offer a broad spectrum of disease-relevant and toxicological models. Our outstanding expertise, many years of experience with partners from the pharmaceutical and biotech industries, and state-of-the-art equipment provide the foundation for our scientific solutions and custom-tailored services. Our special focus is on inhalation toxicology and immunotoxicology.

For efficacy testing of drug candidates we offer disease-relevant models for all therapeutically relevant diseases of the respiratory tract such as COPD, asthma, pulmonary fibrosis, infections, and tumors. We are committed to enabling reliable prediction of the efficacy of drug candidates – by constant development of new methods in collaboration with academic institutions and research centers. For toxicology testing of drug candidates we offer the following services and expertise:

- In-vitro studies (genotoxicity, molecular toxicity, screening assays)
- Ex-vivo studies (e.g. precision-cut lung slices)
- In-vivo studies (relevant species, single-dose and repeated-dose toxicity, reproductive toxicity)
- Safety pharmacology (core battery)
- Testing strategies to accompany clients during scientific advice and registration processes
- Track record including biopharmaceuticals, oligonucleotide-based therapeutics, and ATMPs
- Study performance according to OECD GLP, where applicable

Clinical trials

Finding the most appropriate model for your proof of concept and the most suitable study design are challenges we can successfully handle with our excellent medical expertise and strong academic background. We support clients in the development of drugs targeting respiratory and allergic diseases and do patient-oriented research to help people suffering from these conditions. A broad range of challenge models is available for clinical studies on respiratory diseases such as asthma, allergic rhinitis, COPD, and interstitial lung diseases (idiopathic pulmonary fibrosis in particular). Our studies are performed by a highly qualified and dedicated team of physicians, study nurses, and medical documentation specialists, accompanied by an independent quality assurance unit. The following services and infrastructure are available:

- Fraunhofer Challenge Chambers: challenge chambers for proof-of-concept studies with sophisticated study designs, enabling exposure of test subjects to natural pollen, allergen extracts, or ozone
- Inhaled allergen challenge
- Segmental challenge during bronchoscopy
- Exercise testing (spiroergometry)
- Collection and analysis of human samples
- Biomarker analysis
- Imaging: non-invasive MRI techniques
- In-house GMP laboratory for production of intravenous dosage forms of IMPs
- Patient/volunteer database
Research on human embryonic hematopoiesis in a teratoma model

In vertebrates, hematopoietic stem cells (HSCs) are located mainly in the bone marrow. In addition to their ability to self-renew, these cells continuously produce progenitor cells which mature into blood cells. Pathological alterations in the hematopoietic system often have very critical effects and in some cases the only treatment option is bone marrow transplantation. The availability of donors, however, is limited. This is why scientists have long been trying to synthesize HSCs artificially in cell culture systems from stem cells. Despite many decades of research, this goal has not been reached to date. A novel approach to studying the complex environment of functional HSCs is the use of teratoma formation as a model of embryogenesis. Teratomas are germ cell tumors which can be induced by injection of pluripotent stem cells in immunodeficient mice. They include various cell types and progenitors. During teratoma formation, some cells develop into HSCs displaying the functional characteristics of natural HSCs. Within the scope of the REBIRTH cluster of excellence, scientists of the Hannover Medical School together with Fraunhofer ITEM scientists are using this model to investigate possibilities of supporting artificial production of HSCs. Gathered insights are planned to be transferred to cell culture methods, to get closer to the aim of successful de-novo generation of HSCs.

CONTACT
Dr. Vanessa Neuhaus
Phone +49 511 5350-258
vanessa.neuhaus@item.fraunhofer.de

Antibody-mediated neutralization of specific intestinal bacteria

The small and large intestines play an important role in the human immune system, hosting approximately 70 percent of all immune cells. The gut flora represents a key player in this context. Different immunological diseases such as allergies have been increasingly linked to an impaired intestinal immune system. In a project funded by the Fraunhofer research program “Discover”, scientists of the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig have developed a specific antibody with the aim to neutralize certain gut bacteria. Together with scientists from Fraunhofer ITEM, they hypothesized that this would result in an alteration of the intestinal microbiome, thereby directly affecting the immune system and thus modulating the immune response. In a first proof of concept, the aim was to achieve a reduction in disease symptoms and severity in a mouse model of allergic asthma after treatment with this antibody. Indeed, Fraunhofer ITEM scientists observed a substantial reduction of the allergic airway inflammation in the animals after oral antibody treatment. Such a correction of the microbiome, aimed at modulating the immune system, holds promising potential for the development of a novel pharmacotherapeutic approach to treat a whole range of allergic and autoimmune disorders.

CONTACT
Dr. Christina Hesse
Phone +49 511 5350-202
christina.hesse@item.fraunhofer.de
**Pulmonary fibrosis: ex-vivo model for research and drug testing**

Pulmonary fibrosis is a rapidly progressing lung disease, incurable to date and usually fatal. Hallmarks of this medical condition include uncontrolled proliferation of fibroblasts and excessive production and deposition of extracellular matrix. These pathological changes eventually lead to alterations in lung architecture, causing irreversible dysfunction of the organ. Most insights into the underlying pathogenic mechanisms so far have been gained in in-vivo animal models. Although functional and biochemical features in these models closely resemble those found in patients, animal models often do not entirely reflect all features of the disease. Fraunhofer ITEM scientists are developing a novel ex-vivo approach, allowing investigation of the human disease with higher translational relevance. By stimulating ex-vivo lung tissue slices with relevant pro-fibrotic mediators they were able to induce different biomarkers of fibrosis in non-fibrotic human lung tissue. This model can help to further elucidate the pathogenic mechanisms of pulmonary fibrosis; in addition, it can be used for preclinical testing of anti-fibrotic drug candidates. Already diseased tissue can also be evaluated, for example, to study the expression of pro-fibrotic markers or for pharmacological drug testing and preclinical development of new medications.

**Quantification of the local inflammation in the lung by MRI**

The method of segmental lung challenge in humans by local bronchoscopic application of endotoxin was developed at Fraunhofer ITEM several years ago for efficacy testing of novel anti-inflammatory drugs. It includes determination of the inflammatory cell count in the lung lavage fluid collected during bronchoscopy to evaluate the degree of the inflammation. In an ongoing clinical trial, the endotoxin challenge model is used in healthy test subjects to provide the proof of principle for a novel anti-inflammatory drug to treat chronic obstructive pulmonary disease. For this purpose, a GMP process for importing endotoxin from an American supplier and labeling it for clinical trials was first established at Fraunhofer ITEM. To quantify the degree of the local inflammation, the researchers are using a new method in parallel with the inflammatory cell count determined by bronchoscopy: magnetic resonance imaging (MRI). The aim is to quantify the degree of the local inflammation also noninvasively by means of this imaging method. The proof of concept for this method has already been provided for local allergen challenge (Vogel-Claussen et al., Am J Respir Crit Care Med, 2014; Renne et al., Radiology, 2015). A total of 50 test subjects will be included in this trial. Results are expected for mid-2017.

**CONTACT**

**Dr. Christina Hesse**  
Phone +49 511 5350-202  
christina.hesse@item.fraunhofer.de

**Prof. Dr. med. Jens Hohlfeld**  
Phone +49 511 5350-8101  
jens.hohlfeld@item.fraunhofer.de
Mobile patients instead of mobile challenge chambers

Allergen Challenge Chambers (ACCs) allow allergic test subjects to be challenged with constant pollen concentrations in drug trials to evaluate anti-allergic medications. Furthermore, ACCs tend to be used more and more to test formulations for specific immunotherapy (desensitization), as a natural pollen season with low pollen count may, in unfavorable cases, not be sufficient to demonstrate efficacy of an immunotherapy. Comprehensive immunotherapy studies, however, are often performed at many different centers simultaneously, sometimes even in different countries. This is why attempts have been made to reach all study participants in the involved study centers by means of mobile ACCs. Fraunhofer ITEM is pursuing a contrary approach with its Fraunhofer ACC: the ACC does not travel to patients, but patients travel to the Fraunhofer ACC. Recently, another comprehensive immunotherapy trial based on this concept was successfully completed in the Fraunhofer ACC. In the course of this study, over 300 test subjects from three different countries – Germany, Poland, and Spain – traveled to Hannover before and after the treatment under evaluation, to undergo challenge with grass pollen in the Fraunhofer ACC. Language barriers were overcome by using interpreters. Feedback from patients was positive without exception, despite the long distances some of them had to overcome, and the study sponsor equally rated the study a success. The concept of “mobile patients” thus can continue to be used in future multinational trials.

Production of therapeutic phages for efficacy and infection studies

Phages have been known for a long time to offer an efficient alternative to antibiotics. Despite only few side effects, however, they have not become firmly established in the Western market so far, due to the broad availability of antibiotics. The Division of Pharmaceutical Biotechnology has already built up expertise in GMP manufacturing of therapeutic bacteriophages. As a result of the ongoing public debate about increasing resistances to antibiotics and the search for alternatives motivated thereby, the demand for such expertise has been rekindled. In a first collaborative project with Leibniz Institute DSMZ (German Collection of Microorganisms and Cell Cultures GmbH), Fraunhofer ITEM scientists are developing manufacturing steps for the production of two *Acinetobacter baumanii* phages, geared to GMP quality requirements. The phages thus produced will be tested as anti-infective agents against *A. baumanii* in a murine infection model at Charité in Berlin. To this end, Fraunhofer ITEM scientists have collaborated with colleagues from Leibniz Institute DSMZ to develop cultivation strategies for *Acinetobacter* host strains and phages and establish suitable primary recovery techniques for preliminary treatment of the phage lysate. The next step will be to develop cost-efficient purification methods for the phage lysate, aimed at removing endotoxins from gram-negative *A. Baumanii* in particular as completely as possible. These activities will further enhance Fraunhofer ITEM’s expertise in the production of therapeutic phages.

CONTACT
Dr. med. Dipl.-Kfm. Philipp Badorrek
Phone +49 511 5350-8130
philipp.badorrek@item.fraunhofer.de

CONTACT
Dr. Claudius Seitz
Phone +49 531 6181-6347
claudius.seitz@item.fraunhofer.de
Optimization of production cell lines by means of microRNA

Recombinant proteins for therapeutic use in humans are frequently manufactured by means of eukaryotic cell cultures. This is due to the complex glycosylation pattern of such therapeutic proteins. The manufacturing platforms used today for this purpose, consisting of cell lines of human or animal origin and plasmids with special expression cassettes, enable continued optimization. One option to improve cell growth, expression (i.e. productivity) or cell viability is the use of microRNA (miRNA). Via this type of RNA, which is naturally present in cells, biotechnologists can influence the expression of genes that are directly or indirectly involved in the expression of the product gene. The presence of certain miRNA sequences, for example, allows the number of ribosomes in the cell to be increased. A potential limitation of the expression due to translation can thus be avoided. The miRNA can be stably integrated into the cell genome, so that it will be continuously expressed. Alternatively, it is also possible to integrate miRNA into the expression plasmid of the product and achieve its expression in the cell in this way. A choice of expression plasmids with different miRNA sequences can thus be generated, and an expression plasmid tailored to the expression of the specific product gene can then be selected in each case. At Fraunhofer ITEM in Braunschweig, miRNA sequences are an integral part of cell line development.

CONTACT
Simon Schröder
Phone +49 531 6181-6339
simon.schroeder@item.fraunhofer.de

Development of a robust CHO platform for protein production

The biopharmaceutical industry preferably uses animal cells, CHO cells in particular, for the manufacturing of therapeutic glycoproteins. The aim of this project is to develop in-house CHO production cell lines and corresponding bioprocesses for the manufacturing of biopharmaceutical glycoproteins. To establish this technology platform, it is planned to develop the expression of different monoclonal antibodies and highly glycosylated recombinant proteins by means of the in-house CHO suspension cell line. Glycoengineering and cell line engineering shall be used to improve product quality and quantity. This will enable improvements, for example, in cell viability, product yield, or antibody efficacy (antibody-dependent cellular cytotoxicity, ADCC). Furthermore, preservation of a defined glycosylation pattern of the glycoproteins is becoming increasingly important for market authorization of biopharmaceuticals, given that glycoproteins are characterized more and more by means of their glycosylation pattern. Based on the research work performed to date, it is intended to develop a CHO cell-based technology platform that will guarantee cost and time-efficient production of a broad variety of glycoproteins still complying with all regulatory requirements.

CONTACT
Dr. Markus Heine
Phone +49 531 6181-6307
markus.heine@item.fraunhofer.de
CHEMICAL SAFETY AND ASSESSMENT
THE general objective of chemical risk assessment methodologies is to facilitate both scientific and data-informed decision-making. The process of chemical risk assessment has both qualitative and quantitative components and is generally composed of four steps: hazard identification, dose-response assessment (i.e. DNEL derivation), exposure assessment, and risk characterization.

Our comprehensive experience at Fraunhofer ITEM covers investigation of chemicals, (nano)particles, fibers, and complex mixtures as they occur at workplaces, in the environment, and in consumer products. Based on our core competencies, we provide information supporting decision-makers in reducing potential risks and enabling safe use of chemical products.

The services offered by Fraunhofer ITEM assist you on the way from risk analysis towards safe products.
Development of test methods and analytical procedures

We offer our clients comprehensive consulting and expert opinions in analytical issues that are often beyond the scope of commercially available routine analyses. In close contact with our clients, we develop custom-tailored analytical strategies. For problem-solving that meets the client’s specific requirements, we offer:

- Development of analytical methods and validation in compliance with the relevant guidelines
- Analytical studies (both GLP and non-GLP) required for registration and authorization
- Target and non-target analysis of inorganic and organic compounds (e.g. aldehydes/ketones, dyes, pharmaceuticals, BTX, PAHs, pesticides, VOCs, SVOCs, metals, and compounds typical of explosives)
- Characterization of complex mixtures in environmental samples and biological matrices
- Structural elucidation of drug substances and natural products and of their metabolites
- Protein mass spectrometry, structural elucidation of modified proteins, de-novo sequencing
- Metabolism research and accompanying analyses to investigate toxicokinetic endpoints
- Development of instruments and methods for measurement, collection, and generation of aerosols
- Development of methods and technologies for controlled inhalation studies with different atmospheres

Toxicology testing of chemical substances

We offer a broad range of toxicological tests enabling assessment of potential risks from chemicals, particles, complex mixtures, and nanomaterials. Depending on our clients’ specific requirements, we develop appropriate testing strategies and, if required, conduct toxicology studies with different routes of administration – with a focus on inhalation toxicology and characterization of inhalable substances. Our service portfolio includes:

- Regulatory assessment by means of standard toxicological tests in compliance with international guidelines (OECD, EU, EPA, or FDA)
- P.R.I.T.® exposure system for in-vitro exposure of cells and tissues to airborne, soluble, and particulate test substances at air/liquid interfaces
- Characterization of molecular mechanisms of action
- Use of our own toxicological databases (RITA, goRENI, DevTox)
Exposure characterization

To characterize occupational, indoor, and environmental human exposure to gases and aerosols/particles, inhalation exposure in particular, we combine state-of-the-art measurement technology with mathematical modeling tools. Whenever necessary, we provide adaptations to customize a solution to a client’s specific needs or to guarantee its compliance with relevant regulations. We use the following methods for this purpose:

- Physical and chemical measurement of aerosol and vapor emissions such as dusts, (nano)particles, sprays, oil mists and vapors, and microorganisms
- Exposure modeling, calculation, and measurement: quantification and dispersion of pollutants (e.g. by modeling in SprayExpo), measurement methods for spray applications, deposition and absorption modeling, exposure calculation based on existing models
- Development of custom measurement and process technology for dusts and aerosols (PM\textsubscript{10}, PM\textsubscript{2.5}, exhaust gases, nanoparticles)
- Aerosol generation methods (calibration aerosols, nebulization, dry dispersion)
- Process development: development of test methods and analytical procedures

Regulatory research and risk assessment of chemicals

To assess the potential risk from chemical substances – industrial chemicals, biocides, food additives, and human and veterinary medicinal products – including their use in specific products, we use a tiered approach, referred to as integrated testing strategy (ITS). With self-initiated research projects, we contribute to the development of novel assessment strategies to help improve and refine existing risk assessment methods and ultimately to minimize the need for experimental studies, in particular animal studies. Examples of such projects are elucidation of structure-activity relationships ((Q)SAR), category approaches such as read across, the setting up of databases, and further development of the TTC concept.

For risk assessment of chemicals and their registration for a particular use, we offer:

- Data gap analysis and literature search: in cooperation with the sponsor, we determine what data are available and whether additional studies are necessary, and we check whether there is information publicly available about the substance in question.
- Preparation of dossiers: we prepare IUCLID-5 datasets for the studies, perform exposure and risk assessments, and prepare a chemical safety report (CSR) and the registration dossier.
- Consulting and support to develop a registration strategy tailored to your situation.
- Experimental investigations, e.g. for toxicology testing, can be performed directly at Fraunhofer ITEM or are subcontracted to other testing institutes. If an external partner is needed, we can assist you in selecting an appropriate partner and in the monitoring of your studies.
- Risk assessment and expert reports: in the form of expert reports, we document the (eco)toxicological properties of substances and assess their risks to human health and the environment, for example for REACH registrations, for biocides, and for contaminations or chemical residues in foods and products.
Risks from pyrrolizidine alkaloids in foods

Due to their toxic potential, pyrrolizidine alkaloids (PA) are unwanted in food products. About three percent of all blossoming plants contain these compounds which serve mostly as protection against herbivores. There are more than 660 pyrrolizidines, about half of which display hepatotoxic effects. The German Federal Institute for Risk Assessment (BfR) has provisionally assessed the risk arising from food products, tea and honey in particular, and recommended a daily dose ≤ 7 ng for 1,2-unsaturated PA. The following structural features are characteristic for the typical toxic effects of PA on the liver and partly also on the lung: PA with 1,2-unsaturated necine structure esterified with at least one branched C₅-carboxylic acid are associated with hepatotoxic, carcinogenic, and mutagenic effects upon cleavage by mixed-function oxidases. Pyroles of this type are highly reactive alkylating agents that can react with nucleophilic groups of nucleic acids and proteins to form adducts. On behalf of BfR, Fraunhofer ITEM is conducting a 28-day oral toxicity study with six different PA. BfR scientists are performing DNA microarray analyses, while Fraunhofer ITEM scientists are carrying out hematological and histopathological examinations of liver and lung. The results of this study will be used for toxicological assessment of PA.

CONTACT
Dr. Otto Creutzenberg
Phone +49 511 5350-461
otto.creutzenberg@item.fraunhofer.de

DevTox website available in Chinese

The long established DevTox website (www.devtox.org), operated by Fraunhofer ITEM, provides the internationally harmonized nomenclature for anomalies observed in developmental toxicology as a reference in hazard and risk evaluation of chemicals, illustrated by numerous images. Recent enhancements include the harmonized categorization for all findings added in the course of the nomenclature update in 2012 and the translation into Chinese characters. The latter is intended to promote the use of recognized nomenclature by experts in China and to support training. An important precondition for this enhancement was an adjustment of the heterogeneous website for multilingual use, allowing all elements including buttons and program components to be combined to a uniform Web page in the selected language. The texts were translated into Chinese by cooperators from the Shanghai Institute of Planned Parenthood Research, the WHO Collaborating Centre, and Fudan University. After completion of the technical implementation and thorough testing, the Chinese version was made available to the public and representatives of the cooperation partners German Federal Institute for Risk Assessment, Charité Berlin, and Fraunhofer ITEM presented the DevTox project at the Annual Conference of the Shanghai Society of Environmental Mutagens on November 1, 2016.

CONTACT
Dr. Rupert Kellner
Phone +49 511 5350-106
rupert.kellner@item.fraunhofer.de
**Test of a method to identify novel chemical risks in the food chain**

On behalf of the European Food Safety Authority (EFSA), Fraunhofer ITEM and FoBiG cooperated in testing a method to identify substances that could pose potential risks to the food chain. This method is based on data from registrations under REACH. The project report is available via the ECHA website (please refer to “Publications”: Bitsch et al., 2016). A set of 100 data-rich substances was selected for the test according to a variety of criteria including tonnage (≥ 1 000 t/a) and NOAEL distribution in repeated-dose studies. Four additional substances were selected as positive controls. The data available for these substances were extracted and assessed in six thematic blocks covering environmental exposure, biodegradation, accumulation in foods, repeated-dose toxicity, genotoxicity, reproductive and developmental toxicity. In each block, scores were allocated according to a predefined scoring scheme. Scores were weighted differently in different scenarios and were finally added up to a total score. With regard to the defined criteria, the substances that reached the highest scores could pose potential risks to the food chain and are therefore candidates warranting further investigation of their properties. Besides the use of experimental data, a scoring system enabling prediction of such data has been developed in addition, to allow also evaluation of substances for which data are scarce. In an EFSA follow-up project with official kick-off in January 2017, the partners will apply the tested method to all substances registered under REACH.

**CONTACT**

Dr. Oliver Licht  
Phone +49 511 5350-334  
oliver.licht@item.fraunhofer.de

---

**Light scattering sensor for the analysis of nanoaerosols**

Light scattering is a widely used method in aerosol measurement, in particular when high time resolution and ease of operation is required. The light scattering properties of polarized light scattered under an angle of 90 degrees can be used to obtain information on mean particle size and mass concentration of aerosols in the submicron size range. A sensor was developed at Fraunhofer ITEM using a 630-nm laser diode as light source, enabling measurement of the mass concentration and mean particle size of aerosols in the size range between 0.2 and 1.5 µm. The device is particularly useful for process control, since it can be easily integrated into a flow system and its readout is independent of the flow rate drawn through. At Fraunhofer ITEM, the sensor is extensively employed for the characterization of highly concentrated condensation aerosols formed in e-cigarettes. The aerosol formed in a puff can be analyzed in detail with high time resolution. In this context, the sensor is a simple and robust tool for product characterization and optimization.

**CONTACT**

Wilhelm Dunkhorst  
Phone +49 511 5350-190  
wilhelm.dunkhorst@item.fraunhofer.de

---

**E-cigarette in the laboratory.**
Studies on the hazardousness of carbon nanotubes

Due to their special physical and chemical properties, carbon nanotubes (CNTs) in a large diversity of modifications are put to use in a broad range of innovative processes and products. Human exposure to these materials is possible primarily in manufacturing processes and during treatment and processing. Studies suggest that long and fiber-like CNTs could have tumor-inducing effects similar to those of asbestos fibers. This is why the German Federal Ministry of Education and Research (BMBF) is funding the joint research project "CaNTser". Within this project, potential tumor-causing effects of fiber-like CNTs after inhalation will be examined at Fraunhofer ITEM. In addition, the mechanism of action of CNTs will be studied by means of gene expression analyses and investigations in cell cultures. The researchers are seeking to identify those features of CNTs that cause, potentiate, or weaken their toxic potential. A main objective of this project is to derive a threshold value for CNTs in order to reduce the risk to humans from exposure to CNTs.

Cabin air quality in aircraft: investigation completed

Air quality inside airplanes has been a subject of debate for over 60 years. The key issues are the questions whether oil fumes from the engines leak into the cabin and/or cockpit via the bleed air system and, if so, whether they pose a health hazard to airline passengers and crew members. To clarify this issue, the European Aviation Safety Agency (EASA) commissioned Fraunhofer ITEM and the Hannover Medical School (MHH) with a study to measure and analyze in-flight cabin and cockpit air quality. Manpower and logistic support for this project were provided by the companies Lufthansa Technik AG, Condor Flugdienst GmbH, and British Airways. The results of this study are now available. During a total of 69 flights, the scientists monitored numerous potential pollutants such as VOCs, aldehydes, organic phosphorous compounds, carbon monoxide, ozone, carbon dioxide, and also particles and aerosols. The results show only low contamination of cabin air, which is largely comparable to little contaminated indoor air. Organophosphates such as tricresyl phosphate (TCP) were found only in trace amounts (< 20 ng/m³) in cabin air. The distribution of pollutants detected in the bleed air-independent Boeing 787 was in a low range, similar to findings in conventional aircraft. In addition, the high air exchange rate (> 20/h) in aircraft assures rapid dilution of airborne pollutants. In the course of the study, the researchers were able to document a reproducible, characteristic dilution pattern for the individual flight phases, independent of the type of aircraft. In view of these findings, the reported health impairments in connection with fume events are difficult to comprehend. One outcome of this study, therefore, was a recommendation to systematically investigate potential health effects by ethically justifiable human exposure studies.

CONTACT
Dirk Schaudien Ph.D.
Phone +49 511 5350-324
dirk.schaudien@item.fraunhofer.de

Dr. Sven Schuchardt
Phone +49 511 5350-218
sven.schuchardt@item.fraunhofer.de
Prediction of respiratory toxicity: prevalidation of the ex-vivo model PCLS

In acute inhalation toxicity studies, animals inhale substances at defined concentrations. Without additional information, it is difficult to estimate the appropriate starting concentration for in-vivo inhalation studies. In the context of REACH and the principle of the 3 Rs, there is an increasing public demand for alternative methods. Fraunhofer ITEM was involved in the standardization and prevalidation of precision-cut lung slices (PCLS) as a suitable ex-vivo alternative method to reduce animal numbers in inhalation toxicology. To this end, lung tissue was exposed to increasing concentrations of 20 industrial chemicals in serum-free culture medium under normal submerged culture conditions. Evaluated endpoints included toxicity (WST-1 assay, LDH assay, and BCA assay) and inflammation (IL-1α). For each endpoint, test acceptance criteria were established. We recently published the final results for all 20 chemicals (Hess et al. 2016 in Toxicology in Vitro). More than 900 concentration-response curves were analyzed. Results obtained for all assay endpoints showed best intra- and inter-laboratory consistency for the data obtained by WST-1 and BCA assays. While WST-1 and LDH indicated toxic effects for the majority of substances, only some of the substances induced an increase in extracellular IL-1α. Two prediction models were developed and showed promising results. Whether or not the model will be used for prediction of in-vivo inhalation toxicity remains open, but it certainly provides the opportunity to save animal lives in future.

CONTACT
Dr. Katherina Sewald
Phone +49 511 5350-323
katherina.sewald@item.fraunhofer.de

PLATOX: validated in-vitro toxicity data of graphene nanoplatelets

Graphene nanoplatelets (GNP) represent a new class of carbon-based nanomaterials, with a thickness dimension in the nanometer range and very attractive technical properties. For example, GNP can increase the mechanical stability and conductivity of composite materials. This is why a variety of GNP have already been introduced to the market, although no adequate risk assessment, for workplaces in particular, has so far been possible, due to the still limited availability of toxicity data. In the PLATOX project, funded under the FP7 SIINN ERA-NET program, three institutions from three European countries have accepted the challenge of generating validated in-vitro data for risk assessment. Fraunhofer ITEM as project coordinator was initially responsible for the selection and physicochemical characterization of seven commercially available GNP to be tested. For the ongoing in-vitro tests, Fraunhofer ITEM has been using primary, lung-relevant cell models and both established and innovative endpoints to determine the (geno)toxic and inflammatory potential of the GNP and enable a ranking regarding their toxic potency. To guarantee validity of the generated data, all work steps have to be comprehensively adapted to the special properties of GNP. The in-vivo relevance of the in-vitro data will be verified by using selected GNP in a 28-day inhalation study in rats. All data generated will eventually be used to perform final risk assessment to improve occupational safety.

CONTACT
Dr. Christina Ziemann
Phone +49 511 5350-203
christina.ziemann@item.fraunhofer.de
Development of medical devices is a complex process taking place in a highly regulated environment. Besides specific technical expertise in this area, compliance with the relevant regulatory requirements is of pivotal importance. In this environment, we conduct research, development projects, and device testing. Our Translational Biomedical Engineering team has several years of experience in the development of medical devices.

Close dovetailing with the institute’s other working groups with scientific or medical focuses allows the team to provide comprehensive support to clients in their development projects, to the point of performing the required pre-clinical and early-phase clinical studies. Cooperation with both internal and external development partners from industry and academia enables flexible responses to project-specific requirements. In the area of quality and risk management, we support qualification of external technology processes.

One focus is on active implants: We develop tailored methods for safety and functionality testing of such implants (in compliance with EN ISO 14791 and ISO 10993) and new accelerated aging models for polymer implants in particular. The second focus is on conducting and assisting the development of novel technologies for administration of medicinal aerosols towards smart drug/device combination products.

The services offered by Fraunhofer ITEM assist you on the way from idea to safe medical device.
Device development and processes suitable for SMEs

Our conceptual development work is reflected in the development of medical devices and test benches. Development of devices is performed either as contract research or supporting other research projects. Whenever required, new test benches are developed in parallel and are made available for testing of newly developed devices. This allows our clients to substantially reduce the obstacles encountered during development of innovative products and the risk of technology transfer failure. Furthermore, within our network we provide biomedical engineering systems for demonstration purposes and prototypes for clinical trials.

Development of active implants: Fraunhofer ITEM scientists are currently developing test methods to determine the long-term behavior of active polymer implants that exceed the known standards of temperature acceleration. Such research is geared towards preventing repeat surgery wherever possible and towards minimizing the risk of implant failure.

Development of medical inhalers: Medical inhaler technology is increasingly evolving from simple, constant drug administration to intelligent, breathing-controlled systems for inhalation treatment with pharmaceuticals. At Fraunhofer ITEM, we develop products and test benches to the point of meeting the requirements for use in first clinical trials or as validated measurement systems. We are thus able to make an important contribution to your development process: from initial explorative research via prototype manufacturing and verification to the first clinical trials. Our aim is to support above all small and medium-sized enterprises in their development projects.

Testing and testing scenarios

Besides the use of standard methods, a focus here is on the development of novel test methods. These include above all in-vitro accelerated aging models for active implants, which are necessary to allow stability testing of such implants that can be expected to be of long-term durability, within a short time span.

The test systems for medical devices intended for use in aerosol and inhalation therapy follow a risk management approach – the relevant standards such as ISO 20072 do not stipulate the application of particular test methods. For example, when it comes to testing novel inhalers for use in neonates, there is a need to develop new test methods, as there are no suitable test systems available.

Testing of active implants: Modern active implants are basically designed for early childhood implantation and 100-year periods of use. In order to ensure compliance with these requirements already during development, accelerated testing must be employed. Whilst exposure to higher temperatures has been a working solution for many applications, thin-film polymer devices face reliability limits with a pure temperature increase. To solve this problem nonetheless, we develop new test methods that make use of a multi-parameter model with elevated pressure and artificial body fluids at high concentrations. By setting up mathematical modeling in parallel, we are able to additionally substantiate the desired long-term life span forecasts.
Testing of medical inhalers: Testing of novel devices with standard methods is often not possible. This is why relevant standards leave scope for action. ISO 20072, for example, does not stipulate the test method to be used for testing of inhalation devices. Quite the contrary, for novel inhalation systems in many cases it is necessary to follow a risk-based approach and adapt existing or develop new test methods. We use standard methods as well, but our focus is on testing novel devices and especially devices used in inhalation circuits for adults and neonates. This includes not only measurements of device performance, but also investigation of any impact the delivered substance may have on the whole ventilator circuit. This might be, for example, blockage of filters or other air-conducting pathways, such as nasal prongs of neonates.

Safety and risk assessment of medical devices

The clinical use of medical devices requires that this use poses no risk to the safety and health of patients and device users. Consequently, risk management plays a pivotal role in the development of medical devices. Based on our experience, we support our partners throughout the development phase in minimizing any risks in compliance with the relevant standards. We support our partners with our expertise in the development and implementation of safety features, the formal implementation of risk management, and any risk mitigation measures that may be required.

Regulatory support to reach market approval of medical devices

An important pillar for success in the development of medical device technology is the regulatory strategy. The earlier this strategy is established, the shorter the time to market. During startup, the focus is frequently on other important questions; therefore, we offer early support to address relevant regulatory issues, especially to small enterprises and startups. This support includes assistance in the selection of an approval strategy, implementation of this strategy, and workshops to sensitize for processes and documentation necessary for market approval. This is particularly important, given that the currently still valid Medical Device Directive will soon be replaced by the much more stringent EU-wide Medical Device Regulation.
Breath-activated administration of dry-powder aerosol to ventilated patients

In the local treatment of lung infections (caused by bacteria or fungi) there is a considerable medical need for local delivery of high doses of active pharmaceutical ingredients (APIs). With up to several 100 mg of API per day, the required local pulmonary dose in this case is two to three orders of magnitude higher than in “traditional” inhalation treatment. In this context, there is an urgent need for further development both of portable and stationary inhalers for use by patients themselves and in particular for the development of aerosol dosing methods for use in combination with ventilation systems in intensive care. For children in particular, their lacking coordination capacities and changes in lung anatomy and breathing mechanics throughout childhood require the development of automated systems that are able to adapt to the individual situation. Sensory in-situ breath monitoring and adjustment of the administered dose thus have to be closely coupled. The development activities at Fraunhofer ITEM are addressing these needs with a system that doses the medical aerosol by means of a miniaturized aerosol valve in the patient’s nosepiece or mouthpiece, controlled based on respiratory mechanics monitoring.

CONTACT
Dr. Gerhard Pohlmann
Phone +49 511 5350-116
gerhard.pohlmann@item.fraunhofer.de

Innovative antimicrobial shield for implants

Insertion of implants, for example of hip or knee endoprostheses, poses the risk of infection and resulting dysfunction of the implant. Such problems are caused by bacteria colonizing the implant surface and subsequently forming a biofilm that is resistant to antibiotic treatment. This is why scientists are investigating in depth potential modifications of implant surfaces, aimed at preventing bacterial colonization. The Fraunhofer-Gesellschaft is internally funding the project “SynergyBoost”, in which the Fraunhofer Institutes IFAM, IME, IZI and ITEM are collaborating to develop novel implant coatings. Due to a combination of antibiotics and silver, these coatings shall be more effective than the products so far available. At Fraunhofer ITEM, the newly developed implant surfaces will be colonized in vitro with the typical bacterial strain Staphylococcus aureus and their antibacterial efficacy will be tested. Further investigations in animal models are also part of the project. In addition to efficacy testing, Fraunhofer ITEM scientists will accompany the development of novel implant coatings to comply with the relevant standards and guidelines, e.g. DIN EN ISO 10993 and DIN EN ISO 14971. To this end, they will create the technical documentation required to apply for marketing approval of this innovative drug/technology combination. The project will further enhance Fraunhofer ITEM’s expertise in its newly established Business Unit “Translational Biomedical Engineering”, where it offers companies and also academic institutions support and assistance in the development of medical devices.

CONTACT
Dr. Sabine Wronski
Phone +49 511 5350-444
sabine.wronski@item.fraunhofer.de
Novel test method to help select the most appropriate inhaler

Inhalation of therapeutics is a cornerstone in the treatment of patients with respiratory diseases. Drug delivery to the lungs is often facilitated by dry-powder or metered-dose inhalers. For each device, a patient has to meet certain requirements to enable optimal inhalation of the drug. The aim of this study, performed in cooperation with the company Mundipharma GmbH and the hospital Fachkrankenhaus Kloster Grafschaft, was to get an overview of the requirements customary inhalers place on a patient’s breathing power. A doctor in his or her office normally has no access to data on inhaler resistance nor on the patient’s breathing power. An unambiguous parameter to evaluate the required and the patient’s actual breathing power would facilitate the selection of a suitable inhaler. Another aim of the study, therefore, was to identify a simple and fast test method to help select the most appropriate inhaler for a particular patient. To this end, the required flow rate of each device was determined by means of a literature search and flow resistance values were measured. These data were used to calculate an optimal and a still acceptable necessary breathing power (P in watts). For the clinical part of the study, the inspiratory flow rate and pressure drop were measured in 21 adults with asthma or COPD and in healthy volunteers, and the peak inspiratory breathing power (PIPO in watts) was then calculated from these measurements. In fact, a single measurement of the PIPO value enables the selection of a suitable inhaler almost independently of the respiratory resistance.

CONTACT
Dr. Gerhard Pohlmann
Phone +49 511 5350-116
gerhard.pohlmann@item.fraunhofer.de

FINAMI project: development of plug connectors for neuro-implants

In the FINAMI (Flexible Individualized Active Medical Implants) project funded by the German Federal Ministry for Economic Affairs and Energy, a consortium of industry and research partners is developing reversible plug connectors for lifetime flexible active medical implants. Within this project, Fraunhofer ITEM is developing a test bench for accelerated life cycle testing, where the aging process of active implants can be artificially accelerated to a high degree to enable analysis of material failure. The project partner Hannover Medical School (cluster of excellence “Hearing4all”) is contributing a novel 3D printing technique using silicon elastomers. The core of the 3D printing technique is a high-performance infrared laser reducing the vulcanization time of typical silicon elastomers from about 1.5 hours to a few hundred milliseconds. It vulcanizes the silicon elastomer so quickly that the melting this material typically undergoes when heated is almost completely avoided. The 3D printing of silicon elastomers allows, for example, plug connectors (connected during surgical intervention) to be encapsulated safely yet revisably. This 3D printer, which at present has the highest resolution worldwide, is intended to be further developed at Fraunhofer ITEM in close collaboration with the project partner. The aims of this development are to enable production of individualized neuro-implants tailored to each patient and a future scale-up to larger prostheses.

CONTACT
Jelena Raisa Pankalla
Phone +49 511 5350-234
jelena.raisa.pankalla@item.fraunhofer.de
PERSONALIZED TUMOR THERAPY
The Division of Personalized Tumor Therapy was set up in December 2010 as a research collaboration between the Fraunhofer-Gesellschaft, the Land of Bavaria, and the University of Regensburg. Right from the start, the team of scientists in Regensburg had been organizationally attached to Fraunhofer ITEM in Hannover as a project group, funded by the Bavarian government for the first five years. After its successful evaluation in November 2016, the project group was included in the financing model of the Fraunhofer-Gesellschaft and became a Fraunhofer ITEM division in January 2017. The division is headed by Prof. Christoph Klein, who is also holding the Chair of Experimental Medicine and Therapy Research of the University of Regensburg.

The focus of this division is on the development of diagnostic tests and innovative models to enable detection of disseminated cancer cells early in the disease and prediction of the response to therapy of metastatic progenitor cells. The newly developed methods for single-cell analysis enable detection and comprehensive characterization of disseminated cancer cells, which are extremely rare. These analyses will then allow targeted development of systemic therapies that promise to be more effective than the therapies so far available. The Division of Personalized Tumor Therapy has been certified by TÜV Süd according to DIN ISO 9001:2015 and thus complies with international standards.

The services offered by this division can assist you on the way from molecular analysis to personalized tumor therapy.
Single-cell analysis

Enrichment, isolation and molecular analysis of rare cells

Our commitment is to drive innovative therapeutic approaches by decoding the underlying mechanisms in complex diseases on a single-cell level. The focus is on solid cancers, e.g. the analysis of circulating tumor cells (CTCs) and disseminated cancer cells (DCCs), however, our technologies can be adjusted to different application areas, such as stem cell therapy. Our expertise ranges from the development and implementation of individual enrichment and staining strategies to the isolation of pure cell populations, down to a single target cell. As an accredited single-cell laboratory and through our cooperation with the University of Regensburg, we have access to a sample biobank generated from single CTCs/DCCs of patients with different cancer types. We use these for biomarker research and target validation, and for many samples a correlation with the clinical follow-up can be established. We thus work in a perfect environment for translational research within clinical studies.

Decoding of single cells

For the development of tailored solutions for single-cell or rare-cell analysis, we offer expert knowledge in next-generation sequencing (NGS) and microarray technologies, in particular at the single-cell DNA and RNA levels. Our in-house developed workflows are optimized for the analysis of clinical low-input or single-cell samples, e.g. cancer cells isolated from body fluids, fine-needle aspirates and tissue specimens. Our workflow integrates quality control assays for optimal sample selection, technical implementation, and bioinformatics evaluation.
Innovative tumor models

In-vitro and in-vivo drug testing

For efficacy testing of drugs in innovative preclinical models representing systemic cancer disease, we offer experience in the generation of cellular models for functional analysis of rare cancer cell populations from fluids, organs, and primary tumors. To this end, we have established technologies allowing expansion of few DCCs or CTCs despite their extremely low abundance. Such preclinical models allow us to perform individualized pharmaceutical drug tests, both in vitro and in vivo, and provide the opportunity to comparatively test drugs on cancer subpopulations.

Advanced preclinical PDX models

Preclinical animal models only partially represent the patient situation. Fraunhofer ITEM in Regensburg is developing optimized PDX (patient-derived xenograft) models allowing more representative preclinical drug testing. Our advanced models are based on patient-derived metastatic precursor cells (DTCs) or circulating tumor cells (CTCs). In addition, we concomitantly generate a human immune system in these models, which infiltrates the human tumors and develops phenotypes (e.g. tumor-associated macrophages) that have been described in patient samples. This allows both the tumor development and the dissemination of cancer cells into different organs to be followed in the presence of human immune cells. Our services include development of individualized preclinical in-vivo models to test in particular immunomodulatory drugs on target cells of systemic disease.

Mathematical modeling and bioinformatics

Multi-level disease modeling

Data analysis and biological process modeling are necessary to facilitate development of innovative therapies and support their clinical application. Therefore, we offer our clients profound data analysis and result visualization as well as aim-oriented mathematical modeling of biological mechanisms, disease progression, and therapeutic effects. We can also assist in experimental planning and statistical evaluation of experiments and patient trials. Our spectrum of methods ranges from feature selection, pattern recognition, machine learning, and network analysis to population dynamics, probability theory, and predictive modeling.

Bioinformatics services

Complex biological questions normally cannot be addressed by generalized “one-fits-all” approaches. Our commitment is to provide tailored bioinformatics solutions that provide a comprehensive yet specific answer to your experimental questions. We offer our clients expertise in bioinformatic analysis of high-throughput data from next-generation sequencing or microarray experiments. The Fraunhofer ITEM bioinformatics experts in Regensburg are focused on analyzing human single-cell omics data. Our expertise ranges from simple gene expression via complex genome reconstruction analyses to the development of novel algorithms and applications. Clients are invited to use our counseling services.
Development of preclinical models from circulating tumor cells

Detection and analysis of circulating tumor cells (CTCs) in peripheral blood from patients with metastatic disease has become a growing focus of biomedical and clinical interest over the past few years – because such disseminated cells can provide important information regarding patient prognosis, disease progression, and the individual’s response to therapy. Besides their quantification, molecular characterization allows the genetic profile of these tumor cells to be analyzed, thereby enabling targeted, personalized treatments. Collection of a blood sample for subsequent isolation of tumor cells, a method also referred to as “liquid biopsy”, offers an alternative non-invasive diagnostic approach in particular for inoperable solid tumors such as small-cell lung cancer (SCLC), a highly malignant form of bronchial carcinoma. Given that tumor cells of this cancer type in most cases have already spread extensively at the time of diagnosis and furthermore tend to become drug resistant after chemotherapy, SCLC patients so far have a poor chance of survival. Despite modern treatment options, the five-year survival rate with this type of tumor is only about 2 percent. Appropriate cell models mimicking the setting in patients as closely as possible and representing the tumor’s molecular properties are thus required to enable development of more efficient therapeutic approaches in the future.

To this end, Fraunhofer ITEM scientists in Regensburg have developed preclinical in-vitro and in-vivo models from patient-derived CTCs, enabling expansion of these important cells. Due to their limited availability (in most cases only 1 to 300 CTCs/ml blood) and cell viability, maintaining the detected CTCs ex vivo in a viable, proliferative state for a prolonged period of time after their isolation poses a great challenge. With the establishment of combined in-vitro and in-vivo approaches, the scientists, therefore, pursued different cultivation strategies. For example, they successfully isolated CTCs from blood samples of two SCLC patients, precultured the cells under optimized conditions, and/or expanded them in a mouse model. Molecular biological analyses showed that these models express SCLC-specific tumor markers such as EpCAM, CD56 or cytokeratin and display the same mutations that can also be found in the patients’ genomes, even after prolonged in-vitro or in-vivo cultivation. Furthermore, comparative genomic hybridization, which is a genetic analysis of the whole genome, confirmed that the developed models indeed reflect the molecular properties of patient-derived CTCs. These new cell models thus represent the actual target cells of systemic therapies, enabling research on metastasis formation and mechanisms of drug resistance as well as testing of novel therapeutic approaches to treat SCLC patients.

CONTACT
Dr. Kathrin Weidele
Phone +49 941 298480-52
kathrin.weidele@item.fraunhofer.de
New mechanisms of early metastatic spread in breast cancer discovered

Over several decades, cancer research pursued the dogma that cancer cells preferentially seed from advanced tumors. This concept was based on the finding that early surgical removal is decisive for curing cancer patients. Recently, however, the validity of this concept has increasingly been questioned because also patients with small tumors develop metastases. Furthermore, the genetic profile of disseminated cancer cells often does not show the expected similarity to the primary tumor. Disseminated cancer cells, as precursors of metastases, frequently seem to derive from early tumor evolution stages. Another finding that did not match the concept of late dissemination was the observation that the number of disseminated cancer cells did not correlate with primary tumor size. This spawned the hypothesis that large tumors might be less able to metastasize than small tumors.

Scientists of the Regensburg-based Fraunhofer ITEM Division of Personalized Tumor Therapy, the Chair of Experimental Medicine and Therapy Research of the University of Regensburg, both headed by Prof. Christoph Klein, and the Department of Hematology and Oncology, led by Prof. Julio Aguirre-Ghiso, at the Icahn School of Medicine at the Mount Sinai Hospital in New York for the first time ever studied mechanisms of early metastatic spread in breast cancer and recently published their seminal results in the renowned scientific journal “Nature” (Hosseini et al., 2016 and Harper et al., 2016). The researcher teams found that breast cancer formation hijacks physiological processes controlling mammary epithelial branching and mammary stem-cell expansion in adolescence and pregnancy, deregulates and then misuses them for tumor cell dissemination. In early stages of cancer development, characterized by low cell density and moderate activation of the oncogene HER2, the steroid hormone progesterone led to increased migration of cancer cells and acquisition of so-called stemness properties, both major prerequisites for metastasis. Interestingly, the same hormone suppresses migration and stemness in advanced tumors, with this reversal of effects being mediated by strong activation of HER2, increased cell density, and so-called microRNAs.

The Regensburg researchers were able to demonstrate that at least 80 percent of metastases were derived from early lesions and that their findings, which they mainly obtained from animal models, are also relevant for human metastatic dissemination. The researchers in New York found out that the interactive process between HER2 and the tumor suppressor gene p38 regulates what is referred to as “epithelial-mesenchymal transition”, which allows stationary mammary gland cells to acquire migratory capacity, a process that also normally takes place in mammary gland development. The conclusion drawn by the researchers is that metastases probably derive from different stages of primary tumor evolution and that the resulting cell heterogeneity needs to be addressed for future therapies to be successful.

CONTACT
Dr. Martin Hoffmann
Phone +49 941 298480-28
martin.hoffmann@item.fraunhofer.de

Isolation of a single cell using a micromanipulator. The genetic profile of disseminated cancer cells often differs from that of the primary tumor.
Fraunhofer ITEM has pooled the competencies from its various divisions in three business units: Drug Development, Chemical Safety and Assessment, and Translational Biomedical Engineering. Another focus is on personalized tumor therapy, a subject area explored by the scientists of the corresponding Regensburg-based division of Fraunhofer ITEM. Below please find the contacts for the different thematic areas and services offered. Please do not hesitate to contact these persons directly, should you have any questions or needs.

**Institute directors**

**Prof. Dr. med. Norbert Krug**  
Director (executive)  
Medical Director  
Phone +49 511 5350-8100  
norbert.krug@item.fraunhofer.de

**Prof. Dr. med. Jens Hohlfeld**  
(Deputy Director)  
Division Director of Airway Research  
Phone +49 511 5350-8101  
jens.hohlfeld@item.fraunhofer.de

**Drug Development**

**Dr. rer. nat. Holger Ziehr**  
Coordinator of the business unit Drug Development  
Division Director of Pharmaceutical Biotechnology  
Fraunhofer ITEM, Braunschweig  
Phone +49 531 6181-6000  
holger.ziehr@item.fraunhofer.de

**Dr. rer. nat. Henning Weigt**  
Coordinator of the business unit Drug Development  
Expert Group Manager Regulatory Research and Support  
Phone +49 511 5350-329  
henning.weigt@item.fraunhofer.de

**Development and manufacturing of active biopharmaceutical ingredients**

**Dr. rer. nat. Holger Ziehr**  
Division Director of Pharmaceutical Biotechnology  
Coordinator of the business unit Drug Development  
Fraunhofer ITEM, Braunschweig  
Phone +49 531 6181-6000  
holger.ziehr@item.fraunhofer.de
Chemical Safety and Assessment

Dr. rer. nat. Annette Bitsch
Coordinator of the business unit Chemical Safety and Assessment
Division Director of Chemical Risk Assessment, Databases and Expert Systems
Phone +49 511 5350-302
annette.bitsch@item.fraunhofer.de

Dirk Schaudien Ph.D.
Coordinator of the business unit Chemical Safety and Assessment
Department of Pathology
Phone +49 511 5350-324
dirk.schaudien@item.fraunhofer.de

Katharina Blümlein Ph.D.
Coordinator of the business unit Chemical Safety and Assessment
Department of Environmental and Bioanalytics
Phone +49 511 5350-213
katharina.bluemlein@item.fraunhofer.de

Preclinical testing

Prof. Dr. rer. nat. Armin Braun
Division Director of Preclinical Pharmacology
Phone +49 511 5350-263
armin.braun@item.fraunhofer.de

Clinical trials

Prof. Dr. med. Jens Hohlfeld
Division Director of Airway Research
Phone +49 511 5350-8101
jens.hohlfeld@item.fraunhofer.de

Dr. med. Dipl.-Kfm. Philipp Badorrek
Department Head of Clinical Airway Research
Phone +49 511 5350-8130
philipp.badorrek@item.fraunhofer.de

Development of test methods and analytical procedures

Dr. rer. nat. Sven Schuchardt
Department Head of Environmental and Bioanalytics
Phone +49 511 5350-218
sven.schuchardt@item.fraunhofer.de

Toxicology testing of chemical substances

Prof. Dr. med. vet. Clemens Dasenbrock
Division Director of Toxicology and Environmental Hygiene
Phone +49 511 5350-408
clemens.dasenbrock@item.fraunhofer.de
**Exposure characterization**

**Dr.-Ing. Katharina Schwarz**  
Department of Aerosol Technology  
Phone +49 511 5350-139  
katharina.schwarz@item.fraunhofer.de

**Dr. rer. nat. Stefan Hahn**  
Group Manager of Exposure Assessment  
Phone +49 511 5350-326  
stefan.hahn@item.fraunhofer.de

**Regulatory research and risk assessment of chemicals**

**Dr. rer. nat. Annette Bitsch**  
Division Director of Chemical Risk Assessment, Databases and Expert Systems  
Phone +49 511 5350-302  
annette.bitsch@item.fraunhofer.de

**Dr. rer. nat. Oliver Licht**  
Division of Chemical Risk Assessment  
Phone +49 511 5350-334  
oliver.licht@item.fraunhofer.de

**Translational Biomedical Engineering**

**Dr. rer. nat. Gerhard Pohlmann**  
Coordinator of the business unit Translational Biomedical Engineering  
Division Director of Translational Biomedical Engineering  
Phone +49 511 5350-116  
gerhard.pohlmann@item.fraunhofer.de

**Prof. Dr.-Ing. Theodor Doll**  
Coordinator of the business unit Translational Biomedical Engineering  
Head of the High-Performance Center Translational Biomedical Engineering  
Phone +49 511 5350-230  
theodor.doll@item.fraunhofer.de

Dr. Pohlmann and Prof. Doll are also your contacts for the following subject areas:

**Device development and processes suitable for SMEs**

**Testing and testing scenarios**

**Safety and risk assessment of medical devices**

**Regulatory support for market approval of medical devices**
Personalized Tumor Therapy

Prof. Dr. med. Christoph Andreas Klein
Division Director of Personalized Tumor Therapy
Manager of the Working Group on Pilot Projects
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-55
christoph.andreas.klein@item.fraunhofer.de

Dr. med. Bernhard Polzer
Manager of the Working Group on Molecular Diagnostics
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-23
bernhard.michael.polzer@item.fraunhofer.de

Single-cell analysis

Dr. rer. nat. Stefan Kirsch
Manager of the Working Group on Biomarkers and Technology Development
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-26
stefan.kirsch@item.fraunhofer.de

Innovative tumor models

Dr. rer. nat. Christian Werno
Manager of the Working Group on Therapy Models
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-51
christian.werno@item.fraunhofer.de

Mathematical modeling and bioinformatics

Dr. rer. nat. Martin Hoffmann
Working Group on Pilot Projects
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-28
martin.hoffmann@item.fraunhofer.de

Dr. rer. nat. Urs Lahrmann
Working Group on Biomarkers and Technology Development
Fraunhofer ITEM, Regensburg
Phone +49 941 298480-29
urs.lahrmann@item.fraunhofer.de
Research of practical utility lies at the heart of all activities pursued by the Fraunhofer-Gesellschaft. Founded in 1949, the research organization undertakes applied research that drives economic development and serves the wider benefit of society. Its services are solicited by customers and contractual partners in industry, the service sector and public administration.

At present, the Fraunhofer-Gesellschaft maintains 69 institutes and research units. The majority of the 24,500 staff are qualified scientists and engineers, who work with an annual research budget of 2.1 billion euros. Of this sum, 1.9 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft’s contract research revenue is derived from contracts with industry and from publicly financed research projects. Almost 30 percent is contributed by the German federal and state governments in the form of base funding, enabling the institutes to work ahead on solutions to problems that will not become acutely relevant to industry and society until five or ten years from now.

International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

With its clearly defined mission of application-oriented research and its focus on key technologies of relevance to the future, the Fraunhofer-Gesellschaft plays a prominent role in the German and European innovation process. Applied research has a knock-on effect that extends beyond the direct benefits perceived by the customer: Through their research and development work, the Fraunhofer Institutes help to reinforce the competitive strength of the economy in their local region, and throughout Germany and Europe. They do so by promoting innovation, strengthening the technological base, improving the acceptance of new technologies, and helping to train the urgently needed future generation of scientists and engineers.

As an employer, the Fraunhofer-Gesellschaft offers its staff the opportunity to develop the professional and personal skills that will allow them to take up positions of responsibility within their institute, at universities, in industry and in society. Students who choose to work on projects at the Fraunhofer Institutes have excellent prospects of starting and developing a career in industry by virtue of the practical training and experience they have acquired.

The Fraunhofer-Gesellschaft is a recognized non-profit organization that takes its name from Joseph von Fraunhofer (1787–1826), the illustrious Munich researcher, inventor and entrepreneur.

www.fraunhofer.de
Fraunhofer Institutes working in related subject areas cooperate in Fraunhofer Groups dedicated to specific topics and fostering a joint presence on the R&D market. The Fraunhofer Alliances facilitate customer access to the services and research results of the Fraunhofer-Gesellschaft. Common points of contact for groups of institutes or departments active in related fields provide expert advice on complex issues and coordinate the development of appropriate solutions along the entire value chain. Fraunhofer Institutes furthermore cooperate in Fraunhofer research projects. For example, Fraunhofer ITEM is a member of the Fraunhofer Group for Life Sciences and the Fraunhofer Nanotechnology Alliance and collaborates with other Fraunhofer Institutes in the joint research project RIBOLUTION. Fraunhofer ITEM is thus well networked in the Fraunhofer-Gesellschaft – successful research requires scientific exchange.

Fraunhofer Group for Life Sciences

Six Fraunhofer Institutes and a Fraunhofer Research Institution, each having proven in-depth expertise in different areas within the life sciences, are involved in this Group: the Fraunhofer Institutes for Biomedical Engineering IBMT, Interfacial Engineering and Biotechnology IGB, Molecular Biology and Applied Ecology IME, Toxicology and Experimental Medicine ITEM, Process Engineering and Packaging IVV, Cell Therapy and Immunology IZI, and the Fraunhofer Research Institution for Marine Biotechnology and Cell Technology EMB. Their combined knowledge of biology, chemistry, biochemistry, biotechnology, medicine, pharmacology, ecology, and nutritional science is pooled and synergized within this Fraunhofer Group. In all these Fraunhofer institutions, the scientists collaborate in interdisciplinary teams, so that tailored know-how concerning information technology, engineering science, and legal requirements is also available. Research and implementation at the client’s facilities thus go hand in hand.

Fraunhofer Nanotechnology Alliance

The Fraunhofer Nanotechnology Alliance covers the whole R&D value chain from application-oriented research to industrial implementation. A focus is on multifunctional coatings for use in the optical, automotive and electronics industries. Special nanoparticles (metals, oxides etc.), carbon nanotubes and nanocomposites are designed and used for actuators, structural materials, and biomedical applications. The Alliance furthermore deals with issues of toxicology and safe handling of nanoparticles – this is where Fraunhofer ITEM is bringing in its expertise. The institutes of this Alliance have focused their activities on the following main topics: nanomaterials, nanobiotechnology, nanoprocessing and handling, nano-optics and electronics, measuring methods and techniques, and technology transfer and consulting.

Research project RIBOLUTION

In the Fraunhofer research project RIBOLUTION, five Fraunhofer Institutes are taking an innovative approach to biomarker screening for modern diagnostic solutions. Their aim is to identify novel biomarkers based on ribonucleic acids that can serve as diagnostic indicators or enable prediction of disease progression or future response to therapy, and develop these to the point of clinical proof of concept with the aid of selected patient cohorts. Fraunhofer ITEM is screening for biomarkers that may serve as diagnostic indicators of chronic obstructive pulmonary disease (COPD), enable monitoring of this disease or prediction of its response to therapy.

www.lifesciences.fraunhofer.de
www.nano.fraunhofer.de
www.lifesciences.fraunhofer.de
Publications

Alberter, B.; Klein, C. A.; Polzer, B.
Single-cell analysis of CTCs with diagnostic precision: opportunities and challenges for personalized medicine.

Measurement of exhaled volatile organic compounds from patients with chronic obstructive pulmonary disease (COPD) using closed gas loop GC-MS and GC-APCI-MS.

RIFM fragrance ingredient safety assessment, elemol, CAS Registry Number 639-99-6.
In: Food and Chemical Toxicology (2016) [epub ahead of print]. doi: 10.1016/j.fct.2016.11.027

RIFM fragrance ingredient safety assessment, 2-Hydroxy-α,α,4-trimethylcyclohexanemethanol, CAS Registry Number 42822-86-6.

RIFM fragrance ingredient safety assessment, β-Guaiene, CAS Registry Number 88-84-6.
In: Food and Chemical Toxicology (2016) [epub ahead of print]. doi: 10.1016/j.fct.2016.11.017

Innovative strategies to develop chemical categories using a combination of structural and toxicological properties.

Assessment of in-vitro COPD models for tobacco regulatory science: Workshop proceedings, conclusions and paths forward for in-vitro model use.
In: ATLA Alternatives to Laboratory Animals 44 (2016), No. 2, pp. 129-66.

Bitsch, A.; Bohlen, M.-L.; Escher, S.; Licht, O.; Oltmanns, J.; Schneider, K.; Wibbertmann, A.
Final report: Testing a procedure for the identification of emerging chemical risks in the food chain.
External scientific report. OC/EFSA/SCER/2014/03
doi: 10.2903/sp.efsa.2016.EN-1050

Morphology and staining behavior of neutrophilic and eosinophilic granulocytes of the common marmoset (Callithrix jacchus).
In: Experimental and Toxicologic Pathology 68 (2016), No. 6, pp. 335-343. doi: 10.1016/j.etp.2016.05.002

Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis.
In: Respiration 92 (2016), No. 2, pp. 98-106. doi: 10.1159/000448288

Booth, J. L.; Duggan, E. S.; Patel, V. I.; Langer, M.; Wu, W.; Braun, A.; Coggleshall, K. M.; Metcalf, J. P.
Bacillus anthracis spore movement does not require a carrier cell and is not affected by lethal toxin in human lung models.
In: Microbes and Infection 18 (2016), No. 10, pp. 615-626. doi: 10.1016/j.micinf.2016.06.004
In: Toxicology Letters 258 (2016), Suppl., p. S141.


Viral infection of the central nervous system exacerbates interieukin-10 receptor deficiency-mediated colitis in SLE mice.

In: PLOS ONE 11 (2016), No. 9, p. e0161883. doi: 10.1371/journal.pone.0161883

Veith, N.; Ziehr, H.; MacLeod, R. A.; Reamon-Buettn, S. M.

Mechanisms underlying epigenetic and transcriptional heterogeneity in Chinese hamster ovary (CHO) cell lines.


Angiopoietin-like protein 4 and cardiovascular function in COPD.

In: BMJ Open Respiratory Research 3 (2016), No. 1, p. e000161. doi: 10.1136/bmjresp-2016-000161


FR-900098, an antimarial development candidate that inhibits the non-mevalonate isoprenoid biosynthesis pathway, shows no evidence of acute toxicity and genotoxicity.


Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study.


Booth, J. L.; Duggan, E. S.; Patel, V. I.; Metcalf, J.; Langer, M.; Coggeshall, K. M.; Braun, A.

Alveolar escape by Bacillus anthracis spores does not require a carrier cell and is not altered by lethal toxin.

In: Journal of Investigative Medicine 64 (2016), No. 4, pp. 960-961. doi:10.1136/jim-2016-000120.101

Borlak, J.; Reamon Buettner, S.-M.

Epigenetic silencing of the lung tumor suppressor cell adhesion molecule 1.


Longitudinal replication of severe asthma exhaled breath phenotypes by the U-BIOPRED electronic nose platform.


Use of computational fluid dynamics for optimization of cell-based in vitro methods in inhalation research.

In: Toxicology Letters 258 (2016), Suppl., p. S141.

Buschmann, J.

Changes introduced with the new OECD 443 method and implications on the toxicological interpretation.

In: Toxicology Letters 258 (2016), Suppl., p. 552.

Creutzengen, O.; Hansen, T.; Schuchardt, S.; Tillmann, T.; Knebel, J.

Method for identification of low soluble, biopersistent dusts (GBS).

In: The Toxicologist 55 (2016), No. 1, p. 119, Abstract PS 1510.

Creutzengen, O.; Hansen, T.; Schuchardt, S.; Tillmann, T.; Knebel, J.

Method for identification of low soluble, biopersistent dusts (GBS).


Creutzengen, O.; Hansen, T.; Schuchardt, S.; Tillmann, T.; Knebel, J.

Method for identification of low soluble, biopersistent dusts (GBS).

In: Toxicology Letters 258 (2016), Suppl., pp. 547, Abstract 189. doi: 10.1016/j.toxlet.2016.06.014


Marmoset monkeys as a model for human allergic asthma.


Evaluation of chemically induced cytoyticity of read across compounds in rat and human lung tissue.


Histopathological findings after 12 months inhalation to nocerica.


Thresholds of toxicological concern – overview of ongoing scientific developments.

In: Toxicology Letters 258 (2016), Suppl., p. 558, Abstract OSC02-003.

Escher, S. E.; Pastor, M.; Carrio, P.; Hoffmann-Doerr, S.; Steiger-Hartmann, T.; Mangeleldorf, I.

Time extrapolation factors for risk assessment: are group-specific extrapolation factors possible?


Farca, L.; Ziemann, C.; Oliveira, H.; Burla, S.; Creutzenberg, O.

In-vitro and in-vivo investigations to obtain validated toxicity data of graphene nanoplatelets.


Identifying limitations of the OECD water-sediment test (OECD 308) and developing suitable alternatives to assess persistence.


Granitzny, A.; Knebel, J.; Densborn, C.; Steinberg, P.; Hansen, T.

In-vitro models for the prediction of idiosyncratic drug-induced liver injury.

In: The Toxicologist 55 (2016), No. 1, p. 239, Abstract PS 205.

Granitzny, A.; Knebel, J.; Steinberg, P.; Hansen, T.

In-vitro modeling of the prediction of idiosyncratic drug-induced hepatotoxicity: pro-inflammatory stimuli are needed to differentiate between IDUI and non-IDUI compounds.


Effects of TRPA1 agonists on murine airways.


Induction of pro-fibrotic biomarkers in precision-cut lung slices (PCLS).

In: European Respiratory Journal 48 (2016), Suppl. 60, OA479. doi: 10.1183/13993003.congress-2016.OA479


Identification of pro-fibrotic biomarkers in precision-cut lung slices (PCLS).

Hesse, S.; Blümlein, K.; Hahn, S.
Describing the effectiveness of sector-specific exposure controls.

Conceptual evaluation and uncertainty of Tier 1 exposure assessment models used under REACH.

Hohlfeld, J.; Biller, H.; Hagedorn, I.; Berliner, D.; Bauersachs, J.; Welte, T.; Vogel-Clausen, J.
Ein neuartiges Studiendesign mit Magnetresonanzbildgebungsverfahren zur Untersuchung des Effekts der Indakaterol/Glycopyrronium-Fixeddosiskombination auf die kardiale Funktion bei COPD-Patienten: die CLAIM-Studie.
doi: 10.1055-s-0036-1572020

Holz, O.; Allers, M.; Gaida, A.; Schuchardt, S.; Hohlfeld, J. M.; Zimmermann, S.
Comparison of COPD-related breath VOCs assessed by a compact high-resolution closed-loop GC-IMS and by standard GC-MS.

Rating the value of COPD-related breath VOCs in models created by linear discriminant analysis.

Inflammatory response to the exposure with ultra-fine particles and ozone.
In: European Respiratory Journal 48 (2016), Suppl. 60, Abstract PA1836.
doi: 10.1183/13993003.congress-2016.PA1836

Functional, histological and biochemical endpoints for assessing antifibrotic efficacy in a rat model of pulmonary fibrosis.

Transient receptor potential (TRP) ion channels activation in vital human precision-cut lung slices lead to bronchoconstriction and is neuropeptide substance p-dependent.

Kosandarasan, G.; Rahmer, H.; Gómez, J.; Schaudien, D.; Brockmeyer, H.; Voepel, I.; Westendorf, A.; Creutzenberg, O.; Ziemann, C.
The PHOENIX project: nano-layered hybrid particles as flame retardant additives – toxicological in-vitro investigations using lung-relevant cell models.
doi: 10.1007/s00210-015-1087-4

Different pathways of inflammamome activation in human precision-cut lung slices (PCLS).

Anti-cancer effects of bevacizumab and cisplatin on cancer cell-invaded human lung cancer xenografts.

Anti-obiotically active compounds as a part of the EU project “PneumoNP”.

Krüger, M.; Fieguth, H. G.; Pfennig, O.; Braun, A.; Sewald, K.
Responses to rhinovirus infection in human lung slices are reduced by rupintrivir.
In: European Respiratory Journal 48 (2016), Suppl. 60, Abstract PA3646.
doi: 10.1183/13993003.congress-2016.PA3646

Cigarette smoke and cigarette smoke condensate induce early biomarkers of inflammation and cytotoxicity in precision-cut lung slices.

Cigarette smoke and cigarette smoke condensate induce inflammation and cytotoxicity in precision-cut lung slices (PCLS).
In: Pneumologie 70 (2016), No. 7, Abstract P42.
doi: 10.1055-s-0036-1584649

Reamonn-Buettner, S. M.; Hiemisch, A.; Voepel, I.; Ziemann, C.
Detection of transcriptomic signature for a senescence-associated secretory phenotype (SASP) in human peritoneal mesothelial cells exposed to multiwalled carbon nanotubes.
In: The Toxicologist 55 (2016), No. 1, p. 583, Abstract PS 583.

Reamonn-Buettner, S. M.; Hiemisch, A.; Voepel, I.; Ziemann, C.
Transcriptome signatures in human peritoneal mesothelial cells after exposure to multiwalled carbon nanotubes support a potential role of cellular senescence in mesothelioma development.
doi: 10.1007/s00210-015-1087-4

Requardt, H.; Hansen, T.; Hampel, S.; Steinberg, P.; Dosenbrock, C.
Investigating the cytotoxicity of different forms of multi-walled carbon nanotubes and their use as a potential drug delivery carrier.
In: Naunyn-Schmiedeberg's Archives of Pharmacology 389 (2016), Suppl. 1, p. 553, Abstract 216.
doi: 10.1007/s00210-015-1087-4

Development of an experimental cell-based approach to evaluate biological effects of aerosols from the application of hair-straightening products in vitro using relevant product application and cell exposure conditions.

Ritter, D.; Knebel, J.; Wronski, S.; Montes, A.; Niehof, M.
Development of an in-vitro testing platform for aerosols containing inhalable antibiologically active compounds as a part of the EU project “PneumoNP”.
In: Toxicology Letters 258 (2016), Suppl., p. S146.

Schmeinck, S.; Bitsch, A.; Genth, H.
Analysis of selected substances from the SkinAb database.
doi: 10.1007/s00210-015-1087-4

Investigation of CeO2 nanoparticle toxicity in a 90-day inhalation test.

Toxicity of CeO2 nanoparticles estimated in a 90-day nose-only inhalation study.
doi: 10.1007/s00210-015-1087-4

Sundarasetty, B. S.; Schneider, A.; Sewald, K.; Rittinghausen, S.; Braun, A.; Figuerredo, C.; Ganser, A.; Striperce, R.
No immunohistologically detectable genotoxicity or proliferation following 90-day inhalation of multi-walled carbon nanotubes.

Merten, C. G.; Oltmanns, J.; Bohlen, M.-L.; Escher, S.; Licht, O.; Macleod, M.; Silano, V.; Georgiadis, N.; Kass, G.
Testing a procedure for the identification of emerging chemical risks in the food chain.

Metcalf, J. F.; Booth, J. L.; Duggan, E. S.; Patel, V. I.; Langer, M.; Braun, A.; Coggeshall, K. M.
Bacillus anthracis spore movement and uptake by cells resident in the human lung are not affected by anthrax lethal toxin.
Theses

Doctoral theses

Felicello, Giancarlo
Identification of translocations in single disseminated cancer cells.
University of Regensburg, 2016

Prezler, Frauke
Quantification of allergic processes in the lung.
Hannover Medical School, 2016

Walter, Dorothee
An alternative model for efficacy testing of exogenous surfactant using the isolated perfused rat lung (IPL).
University of Veterinary Medicine Hannover, 2016

Wang-Lauenstein, Lan
Assessment of chemical-induced local irritation and inflammation in organotypic lung tissue model – PCLS.
Leibniz Universität Hannover, 2016

Wichmann, Judy
Untersuchungen zur Prävention von Asthma in einem Ex-vivo-Lungenmodell unter Verwendung nicht-menschlicher Primaten.
University of Veterinary Medicine Hannover, 2016

Master theses

Detzer, Julia
Evaluation of inflammatory markers induced by exogenous noxae in a human pulmonary co-culture in-vitro system.
Hannover Medical School, 2016

Kodandarama, Geema
Comparative assessment of the (geno)toxic potential of certain (nano)materials, intended to be used as flame retardant additives, using lung-relevant cell models.
University of Duisburg-Essen, 2016

Kuhn, Anna
Adaptation and evaluation of genomic sequence analysis of reads resulting from recurrent stochastic concatenation of MseI fragments of a single cell equivalent.
University of Regensburg, 2015

Laßwitz, Lisa
Effect of rhinovirus infection on asthma phenotype ex vivo.
Hannover Medical School, 2016

Schulz, Laura
Charakterisierung von funktionell immobilisierten humanen Lungenepitheliellen zur Etablierung eines In-vitro-Modells für die toxikologische Untersuchung von luftgetragenen Substanzen.
RWTH Aachen, 2016

Volkwein, Annika
Effect of viral infection on asthma phenotype in precision-cut lung slices.
University of Veterinary Medicine Hannover, 2016

Winterberg, Dorothee
Induktion von profibrotischen Signalwegen in Ex-vivo-Gewebschnitten der Lunge.
Hannover Medical School, 2016

Bachelor theses

Ganiyu-Noibi, Athina
The impact of EpCAM on proliferation and migration of prostate cancer cells.
University of Regensburg, 2016

Möller, Marit
Wiederentwicklung einer API-Produktionsplattform: Generierung einer scFv-produzierenden CHO-Zelllinie und Optimierung der Methodik.
Technische Universität Braunschweig, 2016

Seifert, Bastian
University of Applied Sciences Emden/Leer, 2016

Invited lectures

Dr. Philipp Badorrek
Feasibility in recruitment – views from the sponsor and the investigator.
PCMG Annual Conference 2016
Rome (Italy), June 10, 2016

Dr. Annette Bitsch
Praktische Erfahrungen mit Datenanforderungen für das Biozid-Produkttdossier.
Seminar “Erfahrungen mit der Umsetzung der Biozidprodukteverordnung (BPR) EU 528/2012”
BioCity, Leipzig (Germany), June 2, 2016

Dr. Armin Braun
Mechanistic aspects of sensitization.
Workshop “Dermal exposure and disocyanates: current knowledge and research needs”.
International Isocyanate Institute, Inc. (III)
Düsseldorf (Germany), May 10, 2016

Use of precision-cut lung slices for pharmacological research.
Stanford University
San Francisco, California (USA), May 16, 2016

Particle and endotoxin effects.
Satellite symposium “New understandings in IV filtration relevant to patient care”,
World Congress on Vascular Access
Lisbon (Portugal), June 24, 2016

In-vivo and ex-vivo models of respiratory infection and exacerbation.
Robert Koch Institute
Wernigerode (Germany), September 1, 2016

Nerven und Immunzellen: Duo infernale der Allergie?
11. German Allergy Congress
Berlin, September 29, 2016

Bringing innovative therapies into the clinic considering a highly regulated environment.
Colloquium of the REBIRTH cluster of excellence
Hannover (Germany), November 9, 2016
Contributions to congresses and conferences

Bluemlein, K.; Hesse, S.
Solvent transfer – effectiveness of selected risk management measures (RMMs) on airborne solvent exposure.

Boge, L.; Pankalla, J.; Müller, M.; Knebel, J.; Wronski, S.
Development of in-vitro test systems for inhalation treatment of persistent P aeruginosa lung infection.
15th Fraunhofer Seminar "Models of Lung Disease" Hannover (Germany), January 21-22, 2016

A novel model for human allergic asthma in marmoset monkeys.
5th DZL Annual Meeting Hannover (Germany), February 1-2, 2016

Modeling features of human asthma in marmoset monkeys.
15th Fraunhofer Seminar "Models of Lung Disease" Hannover (Germany), January 21-22, 2016

High-resolution parallel analysis of genome and transcriptome of single disseminated prostate cancer cells.
American Association for Cancer Research (AACR) Annual Meeting 2016 New Orleans, Louisiana (USA), April 16-20, 2016

Danov, O.; Sewald, K.; Creutzenberg, O.; Knebel, J.; Hansen, T.
Effects of carbon black nanoparticles on human cells and tissue extracts.
Nanocare Cluster Meeting Frankfurt/Main (Germany), March 3-4, 2016

Ex-vivo infection with rhinovirus in mouse precision-cut lung slices.
20th European Congress on Alternatives to Animal Testing Linz (Austria), August 24-27, 2016

Danov, O.; Volkwein, A.; Romberg, S.; Obernolte, H.; Braun, A.; Wronski, S.; Sewald, K.
Comparison of rhinovirus infection with HRV1B to poly I:C in mouse precision-cut lung slices.
15th Fraunhofer Seminar "Models of Lung Disease" Hannover (Germany), January 21-22, 2016

Danov, O.; Volkwein, A.; Romberg, S.; Obernolte, H.; Braun, A.; Wronski, S.; Sewald, K.
Respiratory viral infection of HRV1B in mouse precision-cut lung slices.
5th DZL Annual Meeting Hannover (Germany), February 1-2, 2016

Histopathological findings after 12-month inhalation of nanoceria.
82nd Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) Berlin (Germany), February 29-March 3, 2016

Farcał, L.; Ziemann, C.; Oliveira, H.; Burla, S.; Creutzenberg, O.
In-vitro and in-vivo investigations to obtain validated toxicity data of graphene nanoplatelets.
52nd European Congress of the European Societies of Toxicology Seville (Spain), September 4-7, 2016

Granitzny, A.; Knebel, J.; Braun, A.; Steinberg, P.; Dassenbrock, C.; Hansen, T.
Extensive characterization of rat precision-cut liver slices by various viability and functional parameters during 24h culture.
ESTIV 2016 – International Congress of the European Society of Toxicology In Vito (ESTIV)
Juan-Les-Pins (France), October 17-20, 2016

Granitzny, A.; Knebel, J.; Müller, M.; Braun, A.; Steinberg, P.; Dassenbrock, C.; Hansen, T.
Characterization of PMA-differentiated THP-1 cells for the use in transwell co-culture systems and the successful application in a hepatocyte-NPC model for the prediction of iDILI.
ESTIV 2016 – International Congress of the European Society of Toxicology In Vito (ESTIV)
Juan-Les-Pins (France), October 17-20, 2016

TRPA1, a cool receptor as a hot therapeutic target in asthma?
5th DZL Annual Meeting Hannover (Germany), February 1-2, 2016

Heath, H.; Holz, O.; Stein, F.; Hohlfeld, J.; Moll, M.; Schultz, C.
Application of small molecule FRET reporters of proteolytic activity in a study of acute lung inflammation.
5th DZL Annual Meeting Hannover (Germany), February 1-2, 2016

Ex-vivo induction of features displaying early onset pulmonary fibrosis in PCLS.
5th DZL Annual Meeting Hannover (Germany), February 1-2, 2016

Comparative research of measurement methods used to quantify the effectiveness of personal protective equipment against dermal exposure.
7th CeESC – Occupational and Environmental Exposure of Skin to Chemicals Conference Manchester (UK), September 19-21, 2016

Hoffmann, M.; Galle, J.
Stochastic system identification without a model – exploring feasible cell regulation types using piecewise linear functions and different experimental data.
International Conference of Systems Biology 2016 Barcelona (Spain), September 16-20, 2016

Hoffmann, M.; Scheitleit, S.; Hodak, I.; Ulmer, A.; Klein, C. A.
Modeling cellular evolution during lymph node colonization in melanoma patients.
International Conference of Systems Biology 2016 Barcelona (Spain), September 16-20, 2016

Hohlfeld, J. M.
Wirksamkeitsprüfung von Medikamenten im Allergenprovokationsraum.
Expertenforum Allergologie Hannover (Germany), April 15, 2016

Holz, O.
Breath volatile organic compounds in COPD.
15th Fraunhofer Seminar "Models of Lung Disease" Hannover (Germany), January 21-22, 2016

Comparison of breath VOC levels between two COPD studies.
IABR Breath Summit 2016 Zurich (Switzerland), September 14-16, 2016

29th Annual Meeting of the German Society for Environmental Mutation Research (GUM) Munich (Germany), October 12-14, 2016
Active participation in committees

Dr. Luma Baydoun
GMP discussion group “GMP-Gesprächskreis” of the Lower Saxony business inspectorate

Dr. Annette Bitsch
German Federal Institute for Risk Assessment (BfR) Committee for Food Additives, Flavorings and Processing Aids
Working committee on probabilistic exposure and risk assessment
“Probabilistische Expositions- und Risikoabschätzung”
Expert panel 110 on cooling lubricants “Kühlschmierstoffe” of the Association of German Engineers (VDI) Technical Division 1 “Production Technology and Manufacturing Methods”
Reviewer for international journals published by Elsevier (incl. “Regulatory Toxicology and Pharmacology”)

Dr. Katharina Blümlein
Working group on analyses in biological materials “Analysen in biologischem Material” of the German Research Foundation (DFG)

Prof. Dr. Armin Braun
Reviewer for international journals in respiratory medicine and immunology (incl. “Journal of Allergy and Clinical Immunology”)
External assessor for international foundations (incl. the Austrian Science Fund (FWF))
External expert for the German Research Foundation (DFG)
MD/Ph.D. commission “Molecular Medicine” of the Hannover Medical School
Scientific advisory committee of the German Society for Allergology and Clinical Immunology (DGAKI)
Member of the German Center for Lung Research (DZL)

Dr. Jochen Buschmann
Working committee on reproductive toxicity “AK Reproduktionstoxizität” of the toxicology advisory board of the German Committee on Hazardous Substances (AGS)

Dr. Otto Creutzenberg
Reviewer for international journals in particle and fiber toxicology (“Particle and Fibre Toxicology”, “Inhalation Toxicology”)

Prof. Dr. Clemens Dasenbrock
Scientific Council on Electromagnetic Fields of the Swedish Radiation Safety Authority (SSM)
Scientific Expert Group (SEG) of the International Commission on Non-Ionizing Radiation Protection (ICNIRP)
Working group on the research program on electricity grid expansion “Forschungsprogramm Stromnetzausbau” of the Committee on Non-Ionizing Radiation of the German Commission on Radiological Protection
Editorial board of the journal “Experimental and Toxicologic Pathology”

Uta Dörffel
Working group on GEP analytics “GEP-Analytik” of the German Society for Good Research Practice (DGGF)

Dr. Heinrich Ernst
Editorial board of the journal “Experimental and Toxicologic Pathology”
“Guess What” committee of the European Society of Toxicologic Pathology (ESTP)
INHAND (International Harmonization of Nomenclature and Diagnostic Criteria) organ working groups “Soft Tissue” and “Skeletal System”
Reviewer for the international journal “Toxicologic Pathology”

Dr. Sylvia Escher
Threshold of Toxicological Concern Task Force, ILJSI Europe (co-chair)

Dr. Ilona Fleischhauer
Working groups on GEP quality assurance/monitoring “GEP-Qualitätssicherung/Überwachung” and GCP quality management “GCP-Qualitätsmanagement” of the German Society for Good Research Practice (DGGF)
Head of the working committee on quality management “Qualitätsmanagement im VLS” in the Fraunhofer Group for Life Sciences

Dr. Stefan Hahn
Working committee on chemical risk assessment of the German Chemical Society (GDCh)’s division of environmental chemistry and ecotoxicology “Umweltchemie und Ökotoxikologie”

Martina Heina
IT division of the International Association for Pharmaceutical Technology (APV)

Prof. Dr. Dr. Uwe Heinrich
Research Committee of the Health Effects Institute (HEI), Boston, USA
Invited member of the IARC working groups on particles, fibers, diesel engine exhaust, polycyclic aromatic hydrocarbons, metals, irritant gases, and air pollution for the compilation of IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

DFG Senate Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area (MAK Commission): working group on the definition of threshold limit values for dusts; working group on the definition of occupational exposure limits; working group on the classification of carcinogens; ad-hoc working group on heavy metals
Committee on Hazardous Substances (AGS) under the German Federal Minister of Labor and Social Affairs; AGS Subcommittee III (UA III); Subcommittee III: working groups on metals (chairman) and on fibers/dust
Scientific advisory committee of the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)
Advisory committee of the Institute for Prevention and Occupational Medicine (IPA) of the German Social Accident Insurance (DGUV)
Committee supporting the public authorities responsible for the approval of animal experiments (Animal Protection Commission)
Co-editor of the manual on hazard assessment of environmental pollutants “Gefährdungsabschätzung von Umweltschadstoffen”

Prof. Dr. Jens Hohlfeld
Reviewer for international journals (incl. “American Journal of Respiratory and Critical Care Medicine”, “European Respiratory Journal”, and “Journal of Allergy and Clinical Immunology”)
External expert for the German Research Foundation (DFG)
Steering committee of the research network “Biomedical Research in Endstage And Obstructive Lung Disease Hannover” (BREATHE) within the German Center for Lung Research (DZL)
Scientific advisory group of the European Medicines Agency (EMA)

Dr. Olaf Holz
European Respiratory Society task-force “Exhaled biomarkers in lung disease”
INHAND (International Association of Breath Research) Standardization Focus Group

Michéla Kaiser
Working group on archiving “Archivierung” of the German Society for Good Research Practice (DGGF)
Dr. Rupert Kellner
Counselor for electronic communication and member of the Executive Board of the European Society of Toxicologic Pathology (ESTP)
Global Editorial and Steering Committee (GESC) for the initiative “International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice” (INHAND)

Prof. Dr. Christoph Klein
External assessor for “Lichtenberg Professorships” of the Volkswagen Foundation
External expert for the German Research Foundation (DFG)
Reviewer for international journals in oncology

Prof. Dr. Wolfgang Koch
Reviewer for international journals in aerosol physics and aerosol technology (incl. “Journal of Aerosol Science”, “Aerosol Science and Technology” and “Annals of Occupational Hygiene”)

Dr. Gustav Könnecker
Working group on European chemicals policy “Europäische Chemikalienpolitik” of the 6th governmental commission “Energie- und Ressourceneffizienz”
Integrated REACH project team, German Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support

Prof. Dr. Norbert Krug
External expert for the German Research Foundation (DFG)
Scientific advisory committee of the German Society for Allergology and Clinical Immunology (DGAki)
Board member of the interdisciplinary allergy center of the Hannover Medical School
Chair of the Clinical Trial Board of the German Center for Lung Research (DZL)
Steering committee of the research network “Biomedical Research in Endstage And Obstructive Lung Disease Hannover” (BREATH) within the German Center for Lung Research (DZL)
Advisory board of the expertise network “Asthma und COPD”

Dr. Oliver Licht
German Federal Institute for Risk Assessment (BfR) Committee for Contaminants and other Undesirable Substances in the Food Chain; chair of the panel on per-and polyfluorinated alkyl substances “Per- und Polyfluoralkylsubstanzen (PFAS)”
Expert panel “Basic module and perfluorinated tensides” of the German Federal Institute for Risk Assessment’s MEAL (= meals for exposure assessment and analysis of foods) study within the Total Diet Study (TDS) in Germany
Working committee on regulatory toxicology “Regulatorische Toxikologie” of the German Society of Toxicology within the German Society of Clinical and Experimental Pharmacology and Toxicology (DGPT)
Public relations delegate of the German Society of Toxicology

Dr. Norbert Lüthe
Working group on electronic data processing “EDV” of the German Society for Good Research Practice (DGGF)
Fraunhofer quality management network

Dr. Neophytos Papamichael
Working committee on quality management “Qualitätsmanagement im VLS” in the Fraunhofer Group for Life Sciences
GMP discussion group “GMP-Gesprächskreis” of the Lower Saxony business inspectorate

Dr. Bernhard Polzer
External assessor for the Wilhelm Sander Foundation for Cancer Research
External assessor for the Medical Research Council (UK)

Priv.-Doz. Dr. Susanne Rittinghausen
Editorial board of the journal “Experimental and Toxicologic Pathology”
Co-optive member of the ESTP board: representative for nomenclature “Guess What” committee of the European Society of Toxicologic Pathology (ESTP)
Global Editorial and Steering Committee (GESC) for the initiative “International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice” (INHAND)
INHAND (International Harmonization of Nomenclature and Diagnostic Criteria) organ working groups “Respiratory System”, “Endocrine System”, “Soft Tissue”, and “Special Senses”, and working group “Apoptosis”
Associate editor of the international journal “Toxicologic Pathology”

Dirk Schaudien Ph.D.
INHAND (International Harmonization of Nomenclature and Diagnostic Criteria) working group “Non-rodents: minipig”
“Pathology 2.0” committee of the European Society of Toxicologic Pathology (ESTP)
“Webinar” committee of the International Federation of Societies of Toxicologic Pathology (IFSTP)

Dr. Sven Schuchardt
GBM – Society for Biochemistry and Molecular Biology
Leibniz-Institut für Analytische Wissenschaften – ISAS – e.V. (Leibniz Institute for Analytical Sciences)
Reviewer for international journals in biochemistry and analytics (incl. “Journal of Proteome Research”, “Proteomics”, “Electrophoresis”, and “Talanta”)

Dr. Katherina Sewald
Reviewer for the international journals “Toxicology Letters”, “Toxicology in Vitro”, “Nanotoxicology”, and “ATOX”
External assessor for international research grants
Steering group of the workshop “Respiratory Toxicity”
Steering group of the workshop “Translational Aspects of in vitro and in vivo Models for Inflammatory Diseases”

Dr. Holger Ziehr
Association of German Engineers (VDI) committee “Technical Good Manufacturing Practice”
GMP discussion group “GMP-Gesprächskreis” of the Lower Saxony business inspectorate
Center for Pharmaceutical Process Engineering (PVZ) at Technische Universität Braunschweig
BioPharma-Translationsinstitut e.V.

Dr. Christina Ziemann
Working group “Genotoxicity” of the DIN Water Practice Standards Committee
Member of the GUM working group on threshold mechanisms of genotoxins
Member of the GUM working group on statistics
Member of the working group on carcinogenesis “Carcinogenese” of the German Society of Toxicology

Teaching activities

Prof. Dr. Armin Braun
Hannover Medical School: lectures in the MD/Ph.D. program “Molecular Medicine”
TRAIN Academy: professional education program “Translational Research & Medicine: From Idea to Product” (lecturer and person in charge of Module 6 “Preclinical development”)”

Dr. Otto Creutzberg
University of Leipzig: lecture on inhalation toxicology in the postgraduate course “Toxicology and Environmental Protection”
Lectures on exposure methods/toxicokinetics and on risk assessment and regulation of particulate matter within the DGGT professional education program for toxicology experts (“Fachtoxikologe/in GT”)”

Dr. Ilona Fleischhauer
University of Braunschweig: lecture on quality assurance in clinical trials (audits)
within the professional training course “Qualifikation zum Prüfarzt/Prüfärztin bzw. Assistenz in klinischen Studien” (GCP basic class)”

Prof. Dr. Jens Hohlfeld
Hannover Medical School: lectures on allergic respiratory diseases

Dr. Stefan Kirsch
University of Regensburg: lectures and hands-on training in molecular oncology in the degree course “Molecular Medicine”; hands-on training in computational biochemistry (database researches) in the degree course “Computational Science”

Dr. Stefan Kirsch
Prof. Dr. Christoph Klein
University of Regensburg: lectures in pathology and molecular oncology in the degree course "Molecular Medicine"; course and hands-on training in molecular oncology; lectures on pathology in the degree course "Human Medicine"

Prof. Dr. Wolfgang Koch
Clausthal University of Technology: lectures on dispersion of pollutants in the atmosphere

Dr. Oliver Licht
RWTH Aachen: lectures in toxicology and risk assessment

Governmental Institute of Public Health of Lower Saxony (NLGA) in Hannover: lecture on substance assessment and risk assessment within the DGFPT course "Regulatory Toxicology"

Dr. Bernhard Polzer
University of Regensburg: lectures in pathology and molecular oncology in the degree course "Molecular Medicine"; course in pathology and hands-on training in molecular oncology; hands-on training in computational biochemistry (database researches) in the degree course "Computational Science"

Prof. Dr. Antje Prasse
Hannover Medical School: lectures on interstitial lung disease

Priv.-Doz. Dr. Susanne Rittinghausen
University of Veterinary Medicine Hannover, Foundation: courses in toxicological pathology

Hannover Medical School: course in laboratory animal pathology

Dr. Anton Rößl
Hamburg University of Applied Sciences: lectures in Good Manufacturing Practice (GMP)

Dirk Schaudien Ph.D.
University of Veterinary Medicine Hannover, Foundation: lectures and courses in special and toxicological pathology

Dr. Katherina Sewald
Hannover Medical School: lectures on allergy and asthma and onalinetics in the degree course "Biomedicine"; lectures on hypertension in the degree course "Biochemistry"; laboratory course in biomedicine; laboratory course in biochemistry: immunology

REBIRTH Autumn Academy for Teachers: course and hands-on training

TWINDOC Hannover: USA – Lower Saxony International Summer Academy

Dr. Natasa Stojanovic
University of Regensburg: course in pathology in the degree course "Molecular Medicine"

Dr. Henning Weigt
TRAIN Academy. lectures on "Principles of quality management – risk management, audits, deviation and change management" and "Preclinical development, phases, costs, and quality assurance"

Dr. Christian Werno
University of Regensburg: lectures on pathology and molecular oncology in the degree course "Molecular Medicine"; hands-on training in molecular oncology

Dr. Holger Ziehr
RWTH Aachen: lectures on "Regulatory Affairs"

Technische Universität Braunschweig: lectures on applied and technical biochemistry

Publicly funded research projects

National

DFG – German Research Foundation
Experimental exposure to air pollutants and sympathetic nerve activity in human subjects
Surfactant inactivation, alveolar collapsibility and their role in the progression to pulmonary fibrosis in animal models of lung injury and fibrosis
From Regenerative Biology to Reconstructive Therapy (REBIRTH 2). Excellence cluster
Clinical Research Unit 311, (Pre-)Terminal heart and lung failure: mechanical relief and repair
Identification of tumor-specific peptides for adjuvant immunotherapy of melanoma patients without distant metastasis

DFG priority program "Mast Cells – Promoters of Health and Modulators of Disease" (SPP 1394)
Characterization of mast cell anatomy and function in primate airways – interaction with the nervous system. DFG Bi2126/3-1

Federal Environment Agency
Chronic toxicity/carcinogenicity assessment of selected nanomaterials.
R&D project 3712 61 206
Support for the use of computerized calculations such as quantitative structure-activity relationships (QSAR methods) to reduce animal experiments under REACH. R&D project 3714 67 413 D
Animal-free assessment under REACH – further development and application of read-across. R&D project 3715 67 418 0
Human biomonitoring of “novel” substances: substance dossier for Lysergical – derivation of toxicological assessment values for human biomonitoring. Project number 58 759
Human biomonitoring of “novel” substances: substance dossier for 2,6-di-tet-buty1-4-methylphenol – derivation of toxicological assessment values for human biomonitoring. Project number 59 000
Survey of interactions between different endocrine axes in aquatic test organisms (literature review). Project number 68 006

Federal Institute for Occupational Safety and Health (BAuA)
Evaluation of tier 1 exposure assessment models under REACH. Research project F 2303
Histopathological examination of samples from a long-term inhalation study. Research project F 2325
Method for the identification of granular biopersistent dusts at workplaces. Research project F 2336
Effectiveness of organizational protective measures: efficacy comparison of different methods for cleaning work clothing. Research project F 2346, enhancement (S18373)
Comparison of inhalation and instillation as testing methods for characterization of granular biopersistent particles (GBP). Research project F 2364
Mode of toxic action of nanocarbons. Research project F 2376
Comparative research on measurement methods for quantification of the protective effect of personal protective equipment against dermal exposure. Investigation no. 517753

Federal Institute for Risk Assessment (BfR)
Further scientific development of the Develfox project and Website translation into Chinese
Subacute in-vivo toxicity study in male rats with six structurally representative pyrrolizidine alkaloids

Federal Ministry of Education and Research (BMBF) action plan for individualized medicine, funding area "Innovations for individualized medicine"
Collaborative project: TurbiCAR
UniCAR-based treatment of CD19-positive lymphoblastic leukemia – subproject "Production of the anti-CD19 target module"

Federal Ministry of Education and Research (BMBF) funding program "Ersatz und Ergänzungsmethoden zum Tierversuch" (alternatives and complements to animal experiments)
ExTox – Explain Inhalation Toxicity
Development of an integrated testing strategy for the prediction of toxicity after repeated-dose inhalation exposure: a proof of concept

Federal Ministry of Education and Research (BMBF) funding program NanoCare: “Auswirkungen synthetischer Nanomaterialien auf den Menschen” (impact of synthetic nanomaterials on human health)
Project: InhalAT90
90-day inhalation testing with CeO2 in the rat and subsequent analysis of gene expression profiles for the early detection of toxic/carcinogenic effects
Project: NanoCOLT
Long-term effect of modified carbon black nanoparticles on healthy and damaged lungs
Project: CaNter
Investigation of the toxic potency of carbon nanotubes following long time inhalation

German Center for Lung Research
Allergy and Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Diffuse Parenchymal Lung Diseases (DPLD)
Unbiased biomarkers for the prediction of respiratory disease outcomes

Asthma
EU project: Innovative Medicines Initiative (IMI) – Understanding Severe Asthma
Unbiased biomarkers for the prediction of respiratory disease outcomes (U-BIOPRED)
WP3 Cross-sectional and longitudinal cohort
WP4 Bronchoscopy studies
WP5 Clinical models
WP6 Pre-clinical laboratory models

EU project: PHOENIX
Synergic combination of high-performance flame retardant nanolayered hybrid particles as real alternative to halogen-based flame retardant additives

EU project: PLATOX
In-vitro and in-vivo investigations to generate validated toxicity data of graphene nanoplatelets vs. a carbon black reference

Statutory Accident Insurance (DGUV)
Evaluation of usability of the physical characteristics of endogenously generated exhaled aerosols in the diagnosis of occupational lung diseases
Summary and evaluation of toxicological and epidemiological studies and derivation of a point of departure and an exposure-risk relationship (ERR)/occupational exposure limit for phenylhydrazine (CAS 100-63-0) for several relevant health endpoints, with a focus on cancer (2015/ERB A-2015)
Summary and evaluation of toxicological and epidemiological studies and derivation of a point of departure and an exposure-risk relationship (ERR)/occupational exposure limit for chromium (II) and (III) compounds for several relevant health endpoints, with a focus on cancer (2016/ERB 7-2016)

International

CEPIC-LRI project: B18
Database on carcinogen dose-response, including information on DNA reactivity, for TTC and beyond

CEPIC-LRI project: ECO18
Identifying limitations of the OECD water-sediment test (OECD 308) and developing suitable alternatives to assess persistence

CEPIC-LRI project: NS-FRAU
Histopathology of rats exposed to barium sulfate nanoparticles by life-time inhalation exposure – effects and bioaccumulation

EASA project: (CAQ) Preliminary Cabin Air Quality Measurement Campaign

EFSA project: Applying a tested procedure for the identification of potential emerging chemical risks in the food chain to the substances registered under Reach – REACH 2

EFSA project: Testing a procedure for the identification of emerging chemical risks in the food chain

ESIG (European Solvents Industry Group): Verifying the effectiveness of solvent risk management measures

EU program FP7: Primomed
Use of PRImate MOdels to support translational MEDicine and advance disease-modifying therapies for unmet medical needs

EU project: ERA-Net "TRANSSCAN"
Analysis of tumor evolution and identification of relapse-initiating tumor cells in non-small cell lung carcinoma

EU project: Eurostars TARGET
Development of next-generation treatment for allergies: targeted glycan-allergen immunotherapy

EU project: ICONS – Integrated Cooperation On Nanotube Safety
An integrated testing strategy for mechanistically assessing the respiratory toxicity of functionalized multi-walled carbon nanotubes

EU project: Innovative Medicines Initiative (IMI) – eTOX
Integrating bioinformatics and chemoinformatics approaches for the development of expert systems allowing the in silico prediction of toxicities

EU project: Innovative Medicines Initiative (IMI) – Understanding Severe Asthma
Unbiased biomarkers for the prediction of respiratory disease outcomes (U-BIOPRED)
WP3 Cross-sectional and longitudinal cohort
WP4 Bronchoscopy studies
WP5 Clinical models
WP6 Pre-clinical laboratory models

EU project: PneumoNP
Nanotherapeutics to treat antibiotic-resistant Gram-negative infections of the lung

EU project: SILICOAT
Industrial implementation of processes to render RCS safer in manufacturing processes

EU project: SILIFE
Production of quartz powders with reduced crystalline silica toxicity

EU project: ToxRisk (HORIZON 2020)
An Integrated European ‘Flagship’ Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century

Cooperation partners

National

ALS Automated Lab Solutions GmbH, Jena
Augsburg University Hospital
Boehringer Ingelheim Pharma GmbH & Co. KG
Cardior Pharmaceuticals GmbH, Hannover
Center of Allergy & Environment (ZAUM), Munich
Charité, Berlin
Charité Research Organization, Berlin
Clausthal University of Technology
Cytena GmbH, Freiburg
ECT Oekotoxikologie GmbH, Flörsheim a. M.
Essen University Hospital
EurA Consult AG, Hamburg Office
EURICE – European Research and Project Office GmbH, Saarbrücken
European Aviation Safety Agency (EASA), Cologne
Federal Environment Agency, Berlin and Dessau
Federal Institute for Occupational Safety and Health (BAuA), Berlin and Dortmund
Federal Institute for Risk Assessment (BfR), Berlin
Federal Office for Radiation Protection (BfS), Salzgitter
FOBIG, Forschungs- u. Beratungsinstitut Gefahrstoffe GmbH, Freiburg
Fraunhofer ICT-IMM, Mainz
Fraunhofer Institute for Applied Solid State Physics IAF, Freiburg
Fraunhofer Institute for Applied Solid State Physics IAF, Freiburg
Fraunhofer Institute for Applied Solid State Physics IAF, Freiburg
Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, Stuttgart and Würzburg
Fraunhofer Institute for Molecular Biology and Applied Ecology IML, Schmallenberg
Free Universität Berlin
Friedrich Schiller University Jena
GATC Biotech, Konstanz
GEMoA Monoclonals GmbH, Dresden
GeneXplain GmbH, Wolfenbüttel
German Cancer Research Center (DKFZ), Heidelberg
German Center for Infection Research (DZIF)
German Center for Lung Research (DZL)
Exhibitions, congresses and workshops

Fraunhofer ITEM presents its research and the services it offers at national and international congresses and exhibitions. In addition, the institute organizes a variety of seminars and workshops. In 2016, the institute hosted or played an active role in the following events:

- **January 21-22, 2016**
  - 15th Fraunhofer Seminar “Models of Lung Disease”
  - Hannover (Germany)

- **February 1-2, 2016**
  - 5th DZL Annual Meeting
  - Hannover (Germany)

- **February 29 - March 3, 2016**
  - 82nd Annual Conference of the German Society of Pharmacology and Toxicology (DGPT)
  - Berlin (Germany)

- **March 4-7, 2016**
  - AAAAI 2016
  - Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  - Los Angeles, California (USA)

- **March 13-17, 2016**
  - SOT 2016
  - 55th Annual Meeting of the Society of Toxicology, including Fraunhofer ITEM Exhibitor-Hosted Session on “Testing approaches towards safe nanoproducts”
  - New Orleans, Louisiana (USA)

- **March 16-19, 2016**
  - World Immune Regulation Meeting X (WIRM)
  - Davos Platz (Switzerland)

- **April 12-14, 2016**
  - in-cosmetics 2016
  - Paris (France)

- **May 13-18, 2016**
  - ATS 2016
  - International Conference of the American Thoracic Society
  - San Francisco, California (USA)

- **May 22-26, 2016**
  - SETAC Europe 2016
  - 26th European Annual Meeting of the Society of Environmental Toxicology and Chemistry
  - Nantes (France)

- **June 6-9, 2016**
  - BIO International Convention 2016
  - San Francisco, California (USA)

- **June 8-10, 2016**
  - PCMG 2016
  - Annual conference of the Pharmaceutical Contract Management Group
  - Rome (Italy)

- **June 11-15, 2016**
  - EAACI 2016
  - European Academy of Allergy and Clinical Immunology Congress
  - Vienna (Austria)

- **June 25-29, 2016**
  - 56th Annual Meeting of The Teratology Society
  - San Antonio, Texas (USA)

- **June 29 - July 1, 2016**
  - 43rd Annual Meeting of the Japanese Society of Toxicology
  - Tokyo (Japan)

- **June 10-14, 2016**
  - Workshop “Novel approaches to fight bacteria”
  - Bremen (Germany)

- **August 24-27, 2016**
  - EUSAAT 2016
  - 20th Annual Congress of the European Society for Alternatives to Animal Testing and 17th Annual Congress of EUSAAT
  - Linz (Austria)

- **September 3-7, 2016**
  - ERS Congress 2016
  - 25th International Congress of the European Respiratory Society
  - London (UK)

- **September 4-7, 2016**
  - EUROTOX 2016
  - 52nd Congress of the European Societies of Toxicology
  - Sevilla (Spain)

- **September 4-9, 2016**
  - European Aerosol Conference (EAC) 2016
  - Tours (France)

- **September 11-14, 2016**
  - 44th Annual Meeting of the European Teratology Society
  - Dublin (Ireland)

- **September 19-21, 2016**
  - OEEC 2016
  - Occupational and Environmental Exposure of the Skin to Chemicals
  - Manchester (UK)

- **September 20-23, 2016**
  - ESTP Annual Congress 2016
  - Congress of the European Society of Toxicologic Pathology
  - Barcelona (Spain)

- **October 9-13, 2016**
  - ISES 2016
  - Annual congress of the International Society of Exposure Science
  - Utrecht (The Netherlands)

- **October 12-14, 2016**
  - BIO-Japan 2016
  - Yokohama (Japan)

- **October 12-14, 2016**
  - 29th Meeting of the German Society for Environmental Mutation Research (GUM)
  - Munich (Germany)

- **October 17-20, 2016**
  - ESTIV 2016
  - 19th International congress of the European Society of Toxicology In Vitro (ESTIV)
  - Juan-les-Pins (France)
Prizes

In 2016, Fraunhofer ITEM researchers were awarded the following prizes for their work:

**Elaine Cabral Serrão**
Prize: Poster prize for the best poster in the “Effector Mechanisms” session of the EAACI 2016 Congress
Prize for the presented poster entitled “A novel disruptive IgE inhibitor: efficacy assessment in non-human primate and human precision-cut lung slices”. Awarded on June 14, 2016 at the Annual Congress 2016 of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna (Austria).

**Arne Gaida**
Prize: Poster prize at the DZL Annual Meeting 2016
Prize for the presented poster entitled “A dual center study to compare breath volatile organic compounds from smokers and non-smokers with and without COPD”. Awarded in February 2016 at the 5th Annual Meeting of the German Center for Lung Research (DZL) in Hannover (Germany).

**Dr. Christina Hesse**
Prize: “Best Abstract of Young Investigators” in the “Clinical Assembly” session of the ERS 2016 Congress
Prize for the abstract entitled “Induction of pro-fibrotic biomarkers in precision-cut lung slices (PCLS)”.

**Sandra Huber**
Prize: Poster prize at the congress “Shaping the Future with Molecular Medicine 2016”
Prize for the presented poster entitled “Parallel analysis of circulating tumor cells and cell-free DNA from blood samples”.
Awarded in October 2016 at the congress “Shaping the Future with Molecular Medicine 2016” in Regensburg (Germany).

**Sebastian Konzok**
Prize: Poster prize at the DZL Annual Meeting 2016
Prize for the presented poster entitled “Bacterial and viral PAMPs and cellular DAMPs lead to activation of the inflammasome in human lung tissue ex-vivo”.
Awarded in February 2016 at the 5th Annual Meeting of the German Center for Lung Research (DZL) in Hannover (Germany).
EDITORIAL NOTES

Coordination and editorial work
Dr. Cathrin Nastevska

Translation
Karin Schlemminger

Photo acknowledgments
Copyright Tom Figiel – p. 14
Andreas Krukemeyer – p. 6
Felix Schmitt Fotografie – pp. 15 and 23 (right)
All other photographs and illustrations: Ralf Mohr, © Fraunhofer ITEM

All rights reserved. Reproduction only with permission from Fraunhofer ITEM.
© Fraunhofer Institute for Toxicology and Experimental Medicine ITEM,
Hannover (Germany) 2017

CONTACTS

Dr. Cathrin Nastevska
Public Relations
Phone +49 511 5350-225
cathrin.nastevska@item.fraunhofer.de

Annegret Seehafer
Marketing
Phone +49 511 5350-402
annegret.seehafer@item.fraunhofer.de
Fraunhofer ITEM
Headquarters
Nikolai-Fuchs-Strasse 1
(main entrance: Stadtfelddamm)
30625 Hannover
Germany
Phone +49 511 5350-0
Fax +49 511 5350-155

Fraunhofer ITEM
Pharmaceutical Biotechnology
Inhoffenstrasse 7
38124 Braunschweig
Germany
Phone +49 531 6181-6001
Fax +49 531 6181-6099

Fraunhofer ITEM
Personalized Tumor Therapy
Biopark 1
Am Biopark 9
93053 Regensburg
Germany
Phone +49 941 298480-23

Further information: www.item.fraunhofer.de